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Believe nothing 
Merely because you have been told it 
Or because it is traditional 
Or because you yourself imagined it 
Do not believe what your teacher tells you 
merely out of respect for the teacher 
But whatever after due examination and analysis 
you fmd to be conclusive to the good 
the benefit, 
the welfare of all beings, 
that doctrine believe and cling to, 
and take it as your guide. 
Gautama Buddha. (563-483 BC). 
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CHAPTER! 
INTRODUCTION 
A blood transfusion is a transplantation of all or part of the blood cells in 
the peripheral blood. The survival of grafted organ transplantation has been 
shown to be prolonged following blood transfusion. The mechanism is thought to 
be immunological in nature. The possibility of a relationship between blood 
transfusion and cancer growth has initiated numerous studies, investigating 
various aspects of transfusions and cancer. Nevertheless, the relative importance 
of this phenomenon is still matter for discussion. Certain aspects of cancer and 
blood transfusions relevant to the experiments reported in this thesis are briefly 
discussed below. 
1.1. Tumor Immunology: 
Cancer is characterized by the uncontrolled and disorderly multiplication of 
abnormal cells. Although the precise mechanism of this malignant process is not 
known, various factors are recognized as being able to initiate that process. 
Chemicals, radiation, genetic factors, repeated trauma, and most recently, viruses 
have been proven to cause or to be strongly associated with certain forms of 
cancer. The concept that cancer is a disease sequential to immunological factors 
dates back to the turn of the century. At the begining of this century Loeb[l] 
demonstrated rejection of incompatible tumor grafts. In the 1940's, Snell[2] 
pointed out role of immunogenicity of tissue in studies of transplantable 
neoplasia to hosts of different histocompatibility constitutions. Lymphocyte 
infiltration into the malignant tissue, unrelated to tissue necrosis, has been 
correlated with a better prognosis. This is indicative of an immunological type of 
host resistance[3]. A lymphoid predominance type of Hodgkin's disease is 
indicative of good prognosis, while the lymphoid depleted type of this tumor 
bears an unfavourable prognosis. A far higher incidence of malignant tumors, 
than would be expected when compared with the normal background population, 
is observed in kidney transplant recipients, who receive immunosuppressive drugs 
continuously[4]. Partial or complete regression of lymphoma or kaposi's sarcoma 
is reported following reduction or cessation of immunosuppressive therapy[5,6]. 
These observations support the concept of a relationship between cancer and 
immunological factors. 
In a bird's eye view, a summary of immunological factors of host and tumor 
is presented below. This is followed by an evaluation of the evidence in support 
of and against a role of immunological factors in tumor genesis and progression. 
It should be stressed that no attempt is made to provide an exhaustive review of 
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The initiation of cancer development and most stages of cancer progression 
are most likely to involve changes at the genetic(DNA) level, as mitosis of a 
cancer cell results in an another malignant cell. Changes in DNA can result in 
different proteins being produced leading to changes in cell membranes. This in 
turn may alter the uptake and release of materials, and alter the adhesiveness 
and cohesiveness, so that invasion and metastases result[?]. Malignant 
transformation may also be accompanied by phenotypic changes in the involved 
cells, including the loss of normal antigenic cell surface components, gain of 
neoantigens and gain of new antigens. Altered antigens, capable of evoking the 
rejection of tumor cells in pre-immunized syngeneic hosts are termed "Tumor 
Associated Transplantation Antigens"(TATA). The presence of TATA is supported 
by results of Foley et al[8] who showed the development of immunity in mice, 
which inhibits the growth of the reimplanted tumor tissue after the removal of 
the primary tumor. Klein et al[9] have demonstrated that immunization of 
syngeneic mice with irradiated tumor cells from a primary sarcoma, leads to 
immunity to a same line of neoplasma, but not to any other of the 12 sarcoma 
cell lines obtained from the same mouse strain. 
Various types of "Tumor Associated Antigens" (TAA) are found to be 
expressed by tumor cells with respect to etiological factors[10,11]: 
a) Virus induced tumors 
Tumor associated antigens induced by a virus are the same in all tumors if 
induced by the same virus in different animals of the same strain, or of 
different strains and even of different species. These antigens are determined by 
the viral genome. Two types of virus-specific antigens have been distinguished, 
according to the location in the cell. 
1) Intra cellular antigens: These antigens can be located in the nucleus or 
cytoplasm of a viral infected cell and are encoded in viral genetic material. 
These antigens are shared by cells infected with a particular virus, irrespective 
of whether or not this viral infection propagates into oncogenesis. The role of 
these antigens in tumor immunity is not known. 
2) Cell surface antigens: These are also viral gene products, coded in viral 
DNA or RNA. These antigens are capable of acting as transplantation antigens, 
i.e.: hosts inoculated with tumor cells displaying surface antigens will develop 
increased resistance to subsequent challenge with the same tumor cells. 
b) Chemically and Physically Induced Tumors 
Antigens associated with these tumors vary from one tumor to another, even 
when the tumors are induced by the same carcinogen in the same strain or even 
in the same host. This polymorphism in antigen expression is unexplained, but 
may reflect the array of DNA changes induced by these carcinogens. 
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c) Embryonic Antigens 
These are an expression or products of antigens normally only found in fetal 
tissue. They are also detected in very small amounts in non-malignant adult cells 
e.g.:a-fetoprotein; carcino-embryonic antigens(CEA). These oncofetal antigens are 
not strictly tumor associated but some of them are capable of functioning as 
TATAs eliciting rejection of tumor in immunized hosts; this indicates a varying 
degree of effectiveness of these antigens in tumor rejection. 
d) Spontaneous Tumors 
Spontaneous tumors are tumors arising in circumstances where no oncogenic 
agent has been proven to be involved. These tumors usually possess very weak or 
no detectable TAAs, but many express fetal antigens on the cell surface. Since 
etiological agents of tumors arising in man are often unknown, many of them 
may belong to this type of tumor. 
The changes in antigenic phenotype of tumor cells can elicit an immune 
response against the tumor antigen. These responses are complex and have not 
yet been fully elucidated. However, several effector mechanisms have been 
implicated in this response i.e.: T-lymphocytes; specific and non-specific 
cytotoxic macrophages; Natural Killer(NK) cell; specific antibodies; natural 
cytotoxic antibodies; and Killer cells[10-12]. The specific properties of these 
mechanisms are summarized below (Figure 1): 
T-Lymphocytes 
During an immune reaction the T-lymphocyte can present itself as a helper 
T-cell(Th), suppressor T-cell(Ts), and cytotoxic T-cell(CTL). Activated T-helper 
lymphocytes can produce a spectrum of activities and subsequently may play a 
pivotal role in the modulation of the immune reaction. Many of the lymphokins 
produced by these T -cells participate in the activation of other effector 
mechanisms implicated in the response. e.g.: 
* The migration inhibiting factor(MIF), the macrophage activating factor(MAF) 
and the chemotactic factor for macrophages(CFM) can lead to the arrest of 
macrophages at the tumor site. They can further initiate phagocytosis by 
macrophages and lead to the development of "activated macrophages". 
* The chemotactic factor(CF) and the leukocyte inhibiting factor(LIF) influence 
the recruitment and activation of neutrophils, capable of lysing tumor cells. 
* The transfer factor(TF) and the mitogenic factors (of which interleukins 1 
and 2 are the most studied) can exert an effect on other lymphocytes. 
* Lymphotoxins which are capable of lysing tumor cells by direct interaction. 
* Interferons (a, {3 and 'Y -interferons): various effects are attributed to these 
with regard to modulation of immune responses. But there is still no 
consensus regarding their overall role in tumor immunology. 
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Legend to Fig. 1: 
~ Cancer cell [!] Macrophage 
~ T -helper cell ~ Polymorphonuclear l leukocyte T -killer cell m Natural killer cell 
w ~ T-memory cell ~ B-lymphocyte ~ T -suppressor cell 
IL-l and 2 Interleukin 1 and 2 TF Transfer factor 
GF Growth factor TNF Tumor necrosis factor 
yiNF y-Interferon PGE2 Prostaglandin E2 
MAF Macrophage activating factor CF Chemotactic factor 
MIF Migration inhibiting factor LIF Leukocyte inhibiting factor 
CFM Chemotactic factor for macrophages LAF Leukocyte activating factor 
T -suppressor cells are capable of suppressing the immune response elicited by 
the host. 
Certain T-lymphocytes recognize tumor associated antigens in association with 
major histocompatibility complex(MHC) products and then differentiate into cells 
endowed with specific cytotoxic activity towards cells with those specific tumor 
antigens. These cells are called Cytotoxic T-lymphocytes(CTL), and may be 
important in the growth control of antigenic tumors. 
Macro phages 
Macrophages demonstrate a variety of functions in reaction to tumor cells. 
They play a part in the processing and presentation of antigens. This is a crucial 
factor with respect to antigenic determinant presentation, in the process of 
triggering T- and B-lymphocytes. Triggering can result in suppression or 
activation of different subsets ofT-lymphocytes. MIF, MAF and CFM and other 
lymphokines produced by T -lymphocytes can result in "activated" macrophages. 
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These cells express an increased non-specific antimicrobial activated and potent 
tumoricidal activity. They are also implicated in releasing factors capable of 
modulating tumor growth. A Tumor necrosis factor(TNF), produced by 
macrophages, can contribute to the killing of tumor cells. In contrast, they are 
also implicated in releasing of certain growth factors that can stimulate the 
growth of tumor cells. Furthermore, these cells are capable of directly activating 
complement C-3, which in turn amplifies the general inflammatory response at the 
tumor site. 
Natural Killer Cells 
These are non-adherent, non-phagocytic cells with spontaneous cytotoxicity 
which can efficiently lyse virus-infected, neoplastic and immature cell types of 
normal tissue. The target structures recognized by NK cells in observed 
cytotoxicity do not show MHC related restriction. NK cell activity is subject to 
both stimulatory regulation, via IFN and IL-2, and suppressive regulation, via 
Prostaglandins E2 (PGE2) produced by macrophages, T-lymphocytes and 
neoplastic cells. The importance of NK cells in opposing tumor growth is as yet 
uncertain. 
B-Lymphocytes 
Antigenic stimulation results in proliferation and antibody formation by 
B-lymphocytes. This response is further modulated by lymphokins produced by 
different T-lymphocyte subsets. The antibodies produced can demonstrate direct 
lytic properties to tumor cells or recruit other cells e.g.: macrophages and killer 
cells, which in turn can show tumoricidal properties. Furthermore, they may 
subvert the cellular immune response to a tumor by forming soluble 
antigen-antibody complexes or masking tumor antigens. 
Killer Cells 
These cells are able to destroy target cells coated with antibodies directed 
against cell surface antigens. Cytotoxicity of these cells is induced by Ig G 
antibodies and is independent of the complement system. This phenomenon is 
known as "antibody dependent cell mediated cytotoxicity "(ADCC). 
The importance of the factors mentioned above is only relative. New antigens 
are not exclusive to malignant tumors; they can also be observed in preneoplastic 
tissues. Furthermore, very often no antigen can be demonstrated on the majority 
of spontaneous tumors. Interpretation of data on tumoricidal effector mechanisms 
is difficult because we are dealing with data from very heterogeneous tumor 
populations like transplantable or spontaneous tumors, different degrees of 
antigenicity, and a difference in the biology of various tumor types[13]. It 
cannot be stressed enough that cells like lymphocytes and macrophages 
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infiltrating into a tumor are not only cytotoxic effector cells. Both types of cells 
in a tumor may participate in the development of the immune reaction (e.g.: 
helper T-cells and macrophages presenting antigens); they may be effector cells 
(CTL and cytotoxic macrophages) or suppressor cells (suppressor T-cells and 
macrophages). Thus the mere presence of macrophages or lymphocytes in a tumor 
does not mean that these cells are tumoricidal cells. Furthermore the tumor 
itself may play a very important role in modulation of the immune response[14]. 
Tumor antigens can lead to either rejection or enhancement of tumor growth, 
depending on the form of interaction with the immune apparatus[l5,16]. 
Formation of soluble tumor antigen antibody complexes or masking of tumor 
antigens by antibody may lead to growth of tumor cells. In addition, tumor cells 
may release factors e.g.: PGE2, which could lead to suppression of NK and Killer 
cell activity. 
Over the course of time, two hypotheses have emerged to explain how 
organisms prevent tumor growth. The basis of these hypotheses is formed by the 
assumption that the daily turnover of cells in the body results in many mutated 
cells, a certain percentage of which are malignant in nature. This assumption 
stipulates that innumerable tumors could develop. The fact is that tumors do not 
occur frequently during a lifetime[17], and furthermore most major mutations are 
known to be incompatible with the survival of the cell. 
The two hypotheses are: 
1) The immune surveillance theory 
This theory attributes a major function to T-lymphocytes: i.e. to recognize 
the mutant cells and to destroy them or inhibit their growth. The T-lymphocyte 
response is implicated to be induced by and directed against the tumor antigens. 
2) The natural resistance theory 
This theory attributes resistance to tumor growth to be the result of NK 
cells, K-cells, granulocytes and macrophages, which are not induced or activated 
by antigens on tumor cells. 
The assumption of the occurrence of de novo tumor cells, based on these 
hypotheses, necessitates a very potent surveillance or natural resistance capable 
of killing these cells, during a very long period. The peak tumor incidence in 
aged people could be explained by the decreased capacity of the immune system 
with passage of time, giving one of the multitude of tumor cells the opportunity 
to "sneak" through the two postulated mechanisms. 
Recent evaluation of evidence has, however increasingly produced arguments 
contradicting the validity of the two hypotheses[18]. Some of the evidence is 
listed below: 
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The incidence of spontaneous tumors in T -cell deficient nude m1ce 1s not 
higher than in immuno-competent animals[19,20]. 
Most tumors that metastasize in normal immuno-competent animals fail to 
do so in nude mice[21]. 
Some murine melanoma cells that are resistant to lysis by T-lymphocytes 
are less metastatic than cells that are susceptible to lysis by T-cells[22]. 
It is mainly tumors of the skin and solid lymphomas which develop in 
immuno-suppressed animals and human patients, whereas according to the 
basic assumption of the hypothesis tumors should arise in all tissues that 
divide rapidly[4,23,24,25]. 
Tumor growth rate in immunologically privileged site~ is not faster, but 
often slower, than that of neoplasms in immunologically exposed sites[26]. 
Spontaneous tumors in both man and animals frequently lack detectable 
antigens[27]. 
Mice bred under sterile conditions, do not have natural cytotoxic 
macrophages. According to mutation frequency such a mouse would develop 
many tumors. This is not the case[28]. 
In mice, NK cell activity is not present before birth or after one year of 
age. The absence of NK cells, however, does not correlate with increased 
tumor incidence. 
Not every type of tumor is found to be sensitive to natural cytotoxic 
antibodies, NK cells or macrophages which would disqualify these cells as 
efficient tools of natural resistance to many of the arising tumor 
cells[29]. 
The above mentioned arguments indicate the failure of each anti-tumor 
system, to kill newly arising tumor cells. However complementation and mutual 
compensation of these systems could be more important and should be considered. 
Furthermore, their effectiveness could be better evaluated if we knew exactly 
the number of de novo arising tumor cells that need to be killed and the variety 
of immunological mechanisms available. In short, we still do not know enough, 
and there is much more to be learned about fundamental immunological 
mechanisms. Studies on the role of host immunity in cancer metastasis have also 
yielded many contradictory results [13,15,30,31]. In many transplantable tumor 
systems, depression of host immunity increases the incidence of experimental and 
spontaneous metastases; in other tumor systems, depression of immunological 
reactivity decreases, or even prevents, metastases or has no influence on the 
growth of a local or disseminated tumor. The basis for these discrepancies could 
be the different etiologies of tumors and the different species employed in these 
studies. But this further illustrates the many factors playing a role in the final 
outcome of tumor growth. Thus, host immunological factors, in interplay with 
tumor cell properties, seem to be involved in the progression of tumors but other 
unidentified factors may be of even greater importance. 
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Yet another example of the complex relationship of immune apparatus and 
tumor growth is demonstrated by the great variety of approaches attempted at 
Immunotherapy i.e.: 
* Non-specific immunization: This employs several reagents e.g.: BCG and 
C.Parvum, which are capable of general stimulation of the lympho-reticular 
system. 
* Active immunization: 
antigens. This entails 
incapable of growth 
immunize the host. 
involves vaccination against the assumed tumor specific 
the use of autologous tumor cells that are rendered 
by irradiation or treatment with mitomycin C, to 
* Passive immunotherapy: entails transfer of anti tumor antibodies to cancer 
patients in order to cause tumor regression or prevent tumor recurrence. 
* Adoptive immunotherapy: involves the transfer of immunocompetence or 
tumor immunity via leukocytes. The latest form of this therapy is lymphokine 
activated killer cells (LAK cells) i.e. host leukocytes are activated by 
lymphokines, notably interleukin-2 (IL-2) in vitro, and then reinjected into 
the host in the belief that their activation has rendered them more effecient 
in their tumoricidal function. This procedure has produced most promising 
results in the fight against cancer growth compared to any of the possiblities 
mentioned above[32]. 
* Biological response modifiers: these are substances, e.g.: Poly A-poly U and 
ABPP, capable of inducing the production of various lymphokines or 
augmenting immune responses in order to control tumor growth. 
1.2. Blood transfusions and Immunology 
Throughout human history, "blood" has been symbolized as possessing many 
mystic and omnipotent powers. In 1492, Pope Innocent VIII was the first human 
to receive a blood transfusion. The Pope and the three blood donors succumbed 
during the procedure; no doubt, evil spirits were blamed at the time. Increasing 
knowledge of blood groups, blood chemistry and technical advances has led to 
ever increasing numbers of blood transfusions being administered in the modern 
practice of medicine. The possibility of successful blood transfusions has resulted 
in the success of many surgical procedures and improved patient care. Coincident 
with greater clinical use of blood transfusions, awareness of the possibility of 
associated morbidity has increased. 
The present known risks of using allogeneic blood transfusions include: 
* mismatched transfusion due to technical errors of typing contributing to grave 
complications[33]; 
* isoimmunization to antigens present in the transfusate[34-36]; 
* risk of hemolytic, febrile reaction; 
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* graft vs host reaction[34-36]; 
* transfusion related acute lung injury[37]; 
* anaphylaxis[38]; 
* transfusion transmitted acquired immuno-deficiency syndrome(AIDS)[39]; 
* transmission of other diseases e.g.: hepatitis, syphilis, malaria, CMV 
virus, Epstein-Barr virus[40,41]. 
In contrast, blood transfusions have also been shown to have a beneficial 
effect on kidney transplant survival[42,43]. However, the mechanism responsible 
for this effect has not been fully elucidated. Evidence suggestive of a 
non-specific immunosuppression mediated by suppressor cells has been presented, 
while on the other hand evidence in support of a specific unresponsiveness 
mediated by anti-idiotypic antibodies which inactivate particular cell clones also 
exists[44,45]. Theories implicating "clonal" deletion of T-cells and selection of 
low responder patients as a result of blood transfusion have been put forward as 
a possible explanation[46,47]. In 1981, by proposing an analogy between tumor 
associated antigens and major histocompatibility antigens, which play a major 
role in transplant outcome, Gantt[48] speculated that the induction of a state of 
immune tolerance by blood transfusions could, via non-specific immune 
suppression, have an effect on tumor growth. In the event of this being true, it 
would be a point of extreme importance because a considerable number of cancer 
patients are anemic or become anemic due to blood loss at operation, and thus 
are regularly transfused. One of the greatest problems in the management of 
malignant disease is the recurrence of metastases. The above phenomenon could 
in fact augment the incidence of metastases, resulting in a poor prognosis for 
cancer patients. For these reasons, an effort was made to test the validity of 
this speculation. 
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CHAPTER2 
RATIONALE AND OBJECTIVES OF THE EXPERIMENTS PERFORMED. 
Gantt's[l] initial proposal of a possible relationship between blood transfusion 
and prognosis of surgically treated cancer patients has stimulated many reports 
of experimental and retrospective clinical studies. A prospective study has also 
been carried out, which looked at possible modulation of tumor growth in 
relation to blood transfusions. Jeekel et al and Francis et al[23,24] were the first 
to report data relating to this speculation. Retrospective reports dealing with 
patients with breast, lung, kidney, colon-rectum, cervix carcinomas and soft 
tissue sarcomas, undergoing "curative" operations produced a varied picture of 
the effects of blood transfusions(Table I). Burrows et al[2] reported clinical data 
providing credence to the speculation of Gantt[l]. In a retrospective study of 122 
patients who had undergone curative surgery for colon-rectum carcinomas, they 
demonstrated significantly lower disease free survival rates for transfused as 
compared to non-transfused patients, the difference being apparent as early as 
6-12 months after surgery. This difference persisted when variables of location, 
tumor stage or post-operative adjuvant therapy were taken into account. 
Blumberg et al and others have confirmed this adverse outcome of patients with 
colon-rectum carcinoma following blood transfusion[3-5]. Furthermore, they 
reported an association between poor prognosis and higher age, lower hemoglobin 
level, longer duration of the operation and the tumor site. However, several 
other retrospective studies, analysing their data in a similar manner, were unable 
to demonstrate an association between detrimental survival rates or disease free 
survival rates and administration of blood transfusions[6-10]. In an prospective 
study, Frankish et al[ll] were also unable to confirm an association between 
perioperative blood transfusion and recurrence of colon-rectum cancer within a 
three year follow-up period. 
Similarly, retrospective data analysis of patients with breast cancer has 
resulted in contradictory reports[12-15]. Nowak, Foster and Miller et al. were 
unable to find any relationship between blood transfusions and prognosis of 
women undergoing surgery for breast cancer[l3-15]. Bickel et al[6], looking at 
survival rates, did fmd a relationship between poor prognosis and a group of 
breast cancer patients receiving blood transfusions. However, of the 68 patients 
in the group analysed, only 17 received blood transfusions. In their exhaustive 
analysis of 169 patients, Tartter et al[12] found a significantly lower cumulative 
5-year disease free survival rate for patients receiving transfusions (51%) 
compared to patients who did not receive blood (65%). However, a markedly 
lower admission hemoglobin value and greater blood loss during surgery were 
found among patients receiving transfusions. Furthermore, a significantly worse 
prognosis was found for patients who had lost a considerable amount of blood as 
compared to those who had lost less blood during surgery. 
Evidence that transfusions affect the prognosis of patients undergoing surgery 
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Table 1: Effect of blood transfusion on prognosis after operation for a tumor. 
Reference Tumor site DFSR/SR* Transfusion** 
effect 
Burrows et al ( 2) 1982 colo-rectum DFSR + 
Blumberg et al ( 3) 1985 colo-rectum DFSR + 
Foster et al ( 4) 1985 colo-rectum SR + 
Parrott et al ( 5) 1986 colo-rectum DFSR/SR + 
Bickel et al ( 6) 1985 colo-rectum SR 
Nathanson et al ( 7) 1985 colo-rectum SR 
Francis et al ( 8) 1985 colo-rectum DFSR 
Ota et al ( 9) 1985 colo-rectum DFSR/SR 
Weiden et al (10) 1984 colo-rectum DFSR 
Frankish et al (11) 1985 colo-rectum DFSR 
T artier et al (12) 1985 breast DFSR + 
Foster et al (13) 1984 breast SR 
Miller et al (14) 1984 breast DFSR 
Nowak et al (15) 1984 breast DFSR 
Bickel et al ( 6) 1985 breast SR + 
T artier et al (16) 1984 lung DFSR + 
Hyman et al (17) 1985 lung SR + 
Bickel et al ( 6) 1985 lung SR + 
Manyonda et al (19) 1986 renal SR 
Moffat eta! (20) 1985 renal SR + 
Rosenberg et al (21) 1985 sarcoma SR + 
Blumberg et a! (22) 1985 cervix DFSR + 
Blumberg et al (22) 1985 prostate DFSR + 
*DFSR: Disease free survival rate. 
SR: Survival rate. 
** +: Detrimental effect 
No effect. 
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for lung cancer has been supplied by three retrospective studies. Tartter et 
al[16] analysed disease free survival rate, while Hyman et al[17] and Bickel et 
al[6] considered survival rates of the patients, and indicated that a blood 
transfusion was a significant prognostic factor for lung cancer patients 
undergoing surgical resection. 
Rosenberg et al[21], in his series of patients with high grade soft tissue 
sarcomas and Blumberg et al[22], with data on cervix cancer, also reported a 
poorer prognosis related to patients receiving blood transfusions. 
In accordance with the clinical retrospective data reported above, similar 
contradictory results are reported from experimental animal studies[23-27]. Using 
a chemically induced sarcoma, Francis et al[23] found a more rapid growth of 
tumor transplants in rats that had received transfusions of allogeneic blood than 
in rats that had not been transfused or had received syngeneic blood. In a 
different model, conflicting results are reported by Jeekel et al[24], who injected 
rats intravenously with a basal cell carcinoma or an adeno-carcinoma cells. More 
pulmonary nodules were found if animals had not received allogeneic transfusions. 
In yet another tumor-host model, Oikawa et al[25] also found inhibition of a 
transplantable fibrosarcoma following allogeneic blood or leukocyte transfusion. 
Zeller et al[27] employing five different models, were unable to fmd differences 
in take rate, induction time, incidence and growth rate of tumors following 
allogeneic blood transfusion. The differences in results of these studies may be 
related to differences in animal blood donors, experimental tumors, routes of 
inoculation and methods of assessment of tumor progression. 
Numerous plausible explanations for the conflicting results of retrospective 
studies can be presented. Retrospective clinical studies are always restrictive in 
the manner in which they can be analysed, as one lacks the control of obtaining 
data which one may consider relevant. The inclusion and exclusion criteria are 
particularly important and may lead to discrepancies. In spite of thorough 
statistical analysis of the data, the possibility of a mathematical artefarct always 
persists. The parameters used in a study can also effect the conclusions reached. 
In studies with rate of recurrence as parameter of prognosis, the frequency of 
follow up and the intensity of investigation can alter the time of first 
recognition of recurrence; thus, studies not conducted under a rigid protocol 
must be regarded with circumspection. Since surgically treated patients are 
considered in these studies, and surgeon-related variables have been shown to be 
of great influence on clinical results obtained[28], this may also bias the results. 
The proposed analogy of blood transfusion leading to specific and nonspecific 
immunosuppresion in organ transplant recipients and a similar effect in cancer 
patients undergoing surgery and receiving blood transfusions, is not a sound one. 
A suppression of the immune apparatus of the host does not necessarily lead to 
enhanced tumor growth; results ranging from increased to decreased tumor 
growth have been reported[29-31]. Furthermore, a transplant recipient receives 
blood transfusions prior to antigenic stimulation of the graft and additionally 
receives immunosuppressive therapy. In a cancer patient, on the other hand, the 
assumed tumor antigens have been present for some time prior to administration 
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of transfusions. Due to heterogeneity of tumor characteristics the results cannot 
be reciprocated. for all tumors, even if blood transfusions result in enhanced 
growth of some tumors. This could explain the contradictory results reported 
above. 
Irrespective of blood transfusions, surgical trauma in itself has been shown to 
exert a profound effect on the host's immune apparatus. Inhibition of 
cell-mediated immunity, decrease in phagocytotic capacity of reticulo-endothelial 
cells, macrophages and neutrophils; decrease in immunoglobulins and complement 
have been reported following surgery. Anesthetic agents, which inevitably 
accompany surgical procedures, have also been implicated in producing 
immunosuppression in patients[35,36]. Furthermore, other factors often present in 
cancer patients i.e.: poor nutritional state, fever, pharmaceutical therapies in the 
form of antibiotics, have also been reported to have similar effects on the 
immune status of the patients[37-39]. Virtually every cancer chemotherapeutic 
agent is shown to be immunosuppressive [40]. Marked depression of 
immune-competence has also been reported following blood loss[41,42]. These 
factors have not been taken into consideration in the reports mentioned above. 
Thus, several factors other than blood transfusions could explain or play a role 
in the adverse effect on tumor growth following transfusion in surgically treated 
patients. Blood transfusion could be an index of either less successful or more 
difficult surgery or other biological behaviour of malignant tumors, a variable not 
measured adequately by histopathological staging. 
These retrospective studies tentatively show that transfusion is associated 
with a worse prognosis than that of patients who do not receive transfusions. A 
more definite answer can only be obtained with experimental studies, since 
elimination of other factors which may influence the retrospective data, or for 
that matter a prospective randomized clinical study, is not feasible. 
These arguments form the theoretical background to the experiments reported 
in this thesis. 
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CHAPTER3 
ANNOTATIONS 
In all studies reported in the following chapters, the central theme of the 
blood transfusion phenomenon and the modulation of tumor growth is present. 
Each report is presented as a manuscript valid on its own merit. However, an 
examination of the studies in the order presented here, may demand clarification 
of minor technical differences present in the studies. A few explanatory remarks 
will be made below to provide a perspective for evaluating all experiments 
centered around a single focus. 
3.1. ANIMALS 
Male rats of inbred Brown Norway (BN) and WAG strains were used. 
Serological and cellular tissue typing has shown the WAG /Rij strain to be 
homozygous for the H-1w haplotype, whereas BN rats are homozygous for the H-
1n haplotype. Thus, BN and WAG rij rats are incompatible for class I and class 
ll antigens of the rat's major histocompatibility complex. The animals were used 
as tumor bearing animals or allogeneic blood donors. They were 16-20 weeks old, 
and weighed 250-300 grams. 
3.2. TUMORS 
Tumor LS 175, which arose spontaneously in BN rats and BC 1618, a radiation 
induced tumor in WAG rat were employed in the studies. Tumor LS 175 is a 
nonimmunogenic sarcoma and tumor BC 1618 is known to be highly immunogenic 
in nature. They reflect the array of immunogenic properties generally used in 
oncological studies. 
Tumor LS 175 is maintained in vivo and in vitro. Cultured LS 175 tumor cells 
were used in the experiments. A possible selection for growth of the tumor cells, 
is inherent to the use of cells obtained from culture. However, in vitro cells 
avoid the disadvantages which render in vivo tumor cells inadequate for 
quantitative and reproducible studies. The greatest disadvantages of employing in 
vivo tumor cells concern factors capable of influencing the incidence of 
metastases after intravenous injection of tumor cells i.e.: 
* difficulty in obtaining a single cell suspension; 
* impossibility of obtaining a similar ratio of viable to nonviable cells; 
* possibility of the presence of different degrees of host infiltrating cells m 
the tumor cell suspension. 
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The effect of experimental procedures on the behaviour of the injected tumor 
cells was assessed by means of a lung nodule assay i.e: Tumor cells were injected 
i.v. into experimental and control rats. After a certain period of time, animals 
were sacrificed and the number of colonies developing on the lung surface were 
counted with the naked eye. The moment of sacrifice of the experimental animals 
was determined by evaluating the number of colonies present on the lung surface 
of untreated control rats. An arbitrary number of colonies was considered 
satisfactory, to avoid extreme numbers of colonies on both side of the scale. 
This led to the performance of the nodule assay on different days post tumor 
inoculation in the consecutive studies. 
The number of tumor cells injected was determined by means of dose-growth 
time experiments. The doses used in the studies are based on the aspiration for a 
practical duration of each experiment of between three and four weeks. Hereby 
the effect of unknown variables on the outcome of the experiments was kept to 
a minimum. 
3.4. EXPERIMENTAL DESIGN 
Knowledge of the precise factors functional in modulating tumor cell 
behaviour is elementary. In order to avoid confusion by the use of standard 
descriptions for different aspects of tumor behaviour, a uniform vocabulary usage 
is recomended. However, the use of certain words in oncological research reports 
is unfortunate. Two such words are "take" and "growth" of tumor cells; these are 
also used by us in the following experimental reports. To clarify the situtation, 
the definition of these words, as employed in this thesis is given below: 
Experimental procedures performed before or around the day of tumor 
injection are considered to affect mainly the "take" of these tumor cells. A 
period of seven days is assumed to be sufficient for the establishment of the i.v. 
injected tumor cells. Therefore, the experimental procedures seven days after 
tumor inoculation are considered to predominantly have an effect on the 
outgrowth of these established artiflcal micrometastases. However, the mode of 
fmal assessment is to count the number of tumor colonies on the lung surface. 
The number of nodules counted is assumed to be correlated to the growth of 
tumor cells. The word "growth" in the following reports is used in this context, 
and not to denote an increase in size of a tumor lesion. 
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CHAPTER4 
MODULATION OF TUMOR GROWTH BY ALLOGENEIC BLOOD TRANSFUSION. 
This chapter was published in J. Cancer Res. and Clin. Oneal. 1986; 111.·50-53. 
Summary 
The effect of a single blood transfusion on the formation and outgrowth of 
experimental lung metastases was assessed in two tumor models in rats. The 
transfusions were given either 1 week before (day -7) or 1 week after (day + 7) 
tumor cell inoculation. The first approach was employed to investigate the effect 
of transfusions on the formation of lung colonies, the second approach to study 
the effect on the outgrowth of established metastases. The fust tumor model 
used was a transplantable, nonimmunogenic sarcoma(LS 175) in BN rats. Animals 
were injected i.v. with loS tumor cells and the number of metastases developing 
in the lungs was counted after 18 days. Experimental animals received 1 ml of 
allogeneic WAG blood, controls were given 1 ml of syngeneic BN blood. A single 
allogeneic transfusion given on day -7 had no effect on the formation of LS 175 
lung colonies, but when given on day + 7, the outgrowth of established metastases 
was stimulated. The second tumor model was a highly immunogenic transplantable 
basal cell carcinoma (BC 1618) in inbred WAG rats. Rats were injected i.v. with 
106 tumor cells and the numbers of lung colonies were counted after 21 days. 
Experimental animals were transfused with 1 ml of BN blood; controls received 1 
ml of WAG blood. Transfusion on day -7 led to a significant inhibition of lung 
metastases, whereas a transfusion on day + 7 had no effect. The results clearly 
indicate that allogeneic blood transfusions can modulate the growth of tumor 
metastasis. Although immunological factors seem to play a crucial role in this 
transfusion phenomenon, there was no clear-cut correlation between the observed 
effects (accelerated tumor growth vs inhibition of metastases) and the type of 
immunomodulation evoked. 
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Introduction 
From clinical and experimental studies it is known that allogeneic blood 
transfusions can have a profound effect on the immune response[1,3]. Blood 
transfusions given to transplant recipients before grafting have been found to 
exhibit a beneficial effect on the survival of kidney grafts, presumably by 
triggering an immunosuppressive mechanism which is however still poorly 
understood[6,14,18]. In conjunction with immunosuppressive drugs, this effect of 
blood transfusions is very powerful and has been demonstrated to be a major 
factor in determining the fate of a kidney graft[13]. Cancer patients undergoing 
surgery frequently receive blood transfusions which, in addition to the 
immunosuppressive effects of anesthesia and the operation procedure itsel£[10,17], 
may further hamper their immune capacity and influence tumor growth and 
metastasis. Retrospective studies by Burrows and Tartter[2] performed in patients 
with colon cancer seem to indicate that blood transfusions may indeed have this 
effect. It was found that the recurrence free survival rate in transfused patients 
was significantly lower than in nontransfused patients. In breast cancer patients, 
a similar trend was observed[19]. In animal studies, detrimental as well as 
beneficial effects of blood transfusions on tumor growth have been 
noted[4,11,12]. The present study was undertaken to investigate the blood 
transfusion phenomenon in two rat tumor models, namely a nonimmunogenic 
tumor in BN rats and an immunogenic tumor in WAG rats. Both animal strains 
have been extensively studied before with regard to the effects of blood 
transfusions on organ graft survival[7,8]. 
Materials and methods 
Animals: Male rats of inbred BN and WAG strains were used. The animals, aged 
16-20 weeks, were bred under specific pathogen free conditions. The animals 
weighed 250-300 grams. 
Tumors: Tumor LS 175 is a nonimmunogenic sarcoma which arose 
spontaneously in the BN rat[9]. The tumor had been transplanted for about 2 
years by s.c.serial passage in the BN strain and was subsequently maintained as a 
stationary culture in Dulbecco's minimum essential medium, supplemented with 
10% fetal calf serum(FCS). To obtain cells for the in vivo experiments free 
floating LS 175 cell clumps were harvested from the tissue culture flasks and, 
after washing, were resuspended in Hank's balanced salt solution(HBSS). Single 
cells were prepared by rinsing the suspension through a pipette. Viability was 
assessed by trypan blue exclusion and was between 80% and 90%. 
Tumor BC 1618 is a radiation induced basal cell carcinoma which has been 
transplanted in syngeneic WAG rats for about 5 years. The tumor is highly 
immunogenic as judged by in vivo immunization challenge experiments carried out 
according to the method described by Prehn and Main[15]. Tumor cell suspensions 
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were prepared from s.c. tumor implants in HESS enriched with 15% FCS. Several 
sections near the periphery of the tumor were selected and diced into small 
fragments. Tumor cells were isolated by mechanical disruption using a razor blade 
mounted on an overhead stirrer as described by Reinhold[16]. Single cells were 
isolated from nondispersed clumps by sieving through nylon gauze. After two 
washings in HESS, the viability was assessed with trypan blue; it was 60%. 
Lung Nodule Assay: Tumor cells were inoculated i.v. into experimental and 
control rats and the number of colonies developing on the lungs were counted 
after 18 days for tumor LS 175 and after 21 days for tumor BC 1618. The lungs 
were excised, rinsed in tap water and subsequently fixed in Bonin's solution. 
Tumor nodules on the lung surface were counted with the naked eye. 
Blood Transfusions: BN rats received a single i.v. injection of 1 m1 heparinized 
whole WAG blood; WAG rats were transfused with 1 ml of BN blood. Control 
animals were injected with 1 m1 syngeneic blood or 1ml HESS. 
Experimental Design 
Two different protocols were followed. In the ftrst approach, allogeneic and 
syngeneic transfusions were given 1 week prior to tumor inoculation. This was 
done to study the effect of transfusions on the formation ("Take") of lung 
metastases. In the second approach, the transfusions were given 1 week after 
tumor injection. This was performed to investigate the effect of blood 
transfusions on the growth of established lung metastases. The significance of 
the differences between groups was determined by the Wilcoxon rank test and 
the X2 test. 
Results 
Effect of transfusions on "take" of metastases fonnation: 
BN and WAG rats were transfused with 1 ml of allogeneic blood, syngeneic 
blood, or HESS 1 week before tumor cell inoculation. The number of lung nodules 
was counted 18 or 21 days after tumor challenge. The results obtained in BN rats 
with tumor LS 175 are given in Table 1. Twelve animals were treated with an 
allogeneic transfusion, 10 received a syngeneic blood transfusion, and 8 rats were 
given HESS. Because of the large variation in number of lung metastases within 
each group, the results were divided into three categories: lungs containing 0-25 
nodules, lungs with 26-100 nodules and lungs with more than 100 nodules. As can 
be seen in Table I, the distribution of metastases was not significantly different 
in the three experimental groups. The majority of animals (50%-62%) fell into the 
ftrst category and had between 0 and 25 lung nodules. The results indicate that 
blood transfusions given on day -7 had no effect on the formation of LS 175 
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lung colonies. The results obtained with tumor BC 1618 in WAG rats (8 animals 
per group) were quite different (Table 2). In this model, allogeneic transfusions 
produced a marked (about 50%) reduction in the number of lung metastases. The 
difference from the controls which had received a syngeneic transfusion was 
statistically significant (P<0.01). 
Table 1: Effect of blood transfusions on the formation of experimental lung 
metastases of tumor LS 175 in BN rats. 
Treatment Fraction of animals with 
HESS 
Syngeneic blood 
Allogeneic blood 
0-25 
nodules 
5/8 
5/10 
7/12 
26-100 
nodules 
3/8 
4/10 
2/12 
> 100 
nodules 
0/8 
1/10 
3/12 
Table 2: Effect of blood transfusion on the formation of experimental lung 
metastases of tumor BC 1618 in WAG rats. 
Transfusion 
Syngeneic 
Allogeneic 
Mean no. of 
nodules (± SD) 
131±17.7 
66 ± 9.9 
Effect of transfusions on tumor growth: 
Range 
98-153 
51- 80 
Median 
133 
66 
One week after tumor cell inoculation, BN and WAG rats were treated with 1 
ml of allogeneic blood, syngeneic blood, or HBSS. The lung nodules were counted 
11 and 14 days later. Table 3 gives the results obtained in BN rats bearing tumor 
LS 175 (16-20 animals per group). Animals treated with allogeneic blood had more 
lung metastases than animals treated with syngeneic blood transfusions or HBSS 
(P<0.025). After a syngeneic transfusion, 69% of the animals had 0-25 metastases 
and 25% showed 26-100 metastases. However, after an allogeneic blood 
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transfusion, this distribution was reversed; 19% of the animals fell into the first 
category and 61% in to the second. The median number of lung colonies in the 
Table 3: Effect of ttransfusion on the growth of established lung metastases of 
tumor LS 175 in BN rats. 
Treatment 
HBSS 
Syngeneic blood 
Allogeneic blood 
Fraction of animals with 
0-25 26-100 > 100 
nodules nodules nodules 
10/20 8/20 2/20 
11/16 4/16 1/16 
3/16 10/16 3/16 
Table 4: Effect of blood transfusion on the growth of established lung metastases 
of tumor BC 1618 in WAG rats. 
Transfusion 
Syngeneic 
Allogeneic 
Mean no. of lung 
nodules (± SD) 
112 ± 19.0 
101 ±24.2 
Range 
63-143 
72-124 
Median 
121 
106 
allogeneic group was 53, in the syngeneic group 22, and in the HESS group 23. 
Blood transfusions given to WAG rats 1 week after inoculation of tumor BC 
1618 (8 animals per group) had no effect on tumor growth. The number of lung 
metastases observed in the group treated with an allogeneic transfusion did not 
differ from the number of nodules found in the syngeneic group (Table 4). The 
mean number of lung nodules was 101 ± 24.2 and 112 ± 19.0 respectively. 
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Table 5: Summary of the effect of blood transfusion on tumor growth in two 
tumor models. 
Tumor model 
LS175 in BN rats 
BC1618 in WAG rats 
Discussion 
Transfusion 
day -7 
No effect 
Inhibition 
Transfusion 
day +7 
Stimulation 
No effect 
The present data, summarized in Table 5, show that allogeneic blood 
transfusions can have an effect on the take and growth of experimental lung 
metastases. In the two models the transfusions used either had an inhibitory 
effect on the formation of lung metastases (tumor BC 1618) or stimulated the 
growth of established metastases (tumor LS 175). These diverse results, i.e. 
inhibition of tumor take versus stimulation of tumor growth, mirrors the 
different effects of blood transfusions on tumor growth as described in the 
literature. Francis and Shenton[ 4] observed stimulation of s.c. tumor growth in 
rats after pretreatment on day -14 with allogeneic blood. In contrast, Oikawa et 
al.[12] found that pretreatment of WKA rats with allogeneic blood on day -7 led 
to inhibition of s.c. tumor growth. Interestingly, the latter authors found that 
the strength of growth inhibition mainly depended on the blood donor strain 
used. Some rat strains induced a very strong inhibition others only a moderate 
inhibition, whereas some strains produced no effect at all. In subsequent 
experiments they further demonstrated that growth inhibition could also be 
produced by other forms of allogeneic immunization, skin grafting being the most 
effective[5]. The comparable effects evoked by allogeneic blood transfusions and 
skin grafting in the above mentioned model suggest that in WKA rats, blood 
transfusions lead to sensitization and not to immunosuppression as might have 
been expected. A similar phenomenon occurs in the BN rats used in the present 
study. From transplantation studies it is known that a single WAG blood 
transfusion given to BN rats leads to sensitization which is reflected in 
accelerated rejection of subsequently transplanted organ grafts[7]. In contrast, 
WAG rats transfused with BN blood exhibit the classical phenomenon of 
transfusion-induced immunosuppression; the response to mitogens is reduced and 
organ grafts are accepted for a prolonged period[8]. Consequently, the two 
models used in the current study could represent the two extremes of the 
transfusion effect spectrum: sensitization in the BN-LS175 model and 
immunosuppression in the WAG-BC 1618 model. Surprisingly, sensitization was 
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associated with accelerated tumor growth whereas transfusion-induced 
immunosuppression led to inhibition of metastases formation. Francis and 
Shenton[ 4] found in their tumor model that allogeneic transfusion led to 
suppression of T -cell reactivity which was associated with accelerated tumor 
growth. Nathenson et al.[ll] showed that in mice, allogeneic transfusions induced 
a depressed mixed leukocyte reactivity whereas natural killer(NK) cell activity 
was increased. In their model, blood transfusions led to a decreased number of 
pulmonary metastases. These examples, combined with our own diverse results 
indicate that the enhanced or decreased growth of tumors following blood 
transfusions is a complicated matter for which several mechanisms, not 
necessarily all immunological, may be responsible. The mechanisms range from 
altered NK cell or macrophage activity, increased or decreased T -cell reactivity 
with corresponding changes in lymphokine production to alterations in humoral 
immunity. All these factors may influence tumor growth; whether the net result 
of the immunomodulation will lead to tumor inhibition or tumor promotion may 
be determined by the ilnmunogenicity of the tumor, sharing of certain epitopes 
on the tumor with antigens on the immunizing cells, and the immunocompetence 
of the host. 
Current immunological studies with transfused, tumor bearing BN and WAG 
rats may help to elucidate the blood transfusion phenomenon, and thus enable its 
manipulation. 
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CHAPTERS 
EFFECT OF ANESTHESIA, SURGERY AND BLOOD TRANSFUSION ON TAKE 
AND METASTATIC GROWTH OF TUMOR CELLS, IN A RAT MODEL. 
This chapter was published in Transplant.Proc. 1987; 19:1473-1474 and Surg. Res. 
Comm. 1987; 2:19-25. 
Summary 
Several retrospective studies have indicated an adverse effect of blood 
transfusion on the survival of surgically treated cancer patients. We have 
investigated the effect of anesthesia, surgery alone and blood transfusions alone 
and in combination on the growth of artificial lung tumor metastases in BN rats. 
Furthermore, the effect of blood transfusions and surgery on the take of tumor 
cells was studied. Abdominal surgery in combination with allogeneic blood 
transfusion and allogeneic blood transfusion alone was found to have a strong 
stimulatory effect on the growth of the metastases. Surgery alone and ether 
anesthesia alone, did not demonstrate this tumor growth enhancing effect. 
Abdominal surgery on day 0 enhanced the take of tumor cells, while blood 
transfusions on day -7 had no effect. The immune status and the local 
environment of the metastases may provide crucial information for understanding 
this phenomenon 
31 
Introduction 
The beneficial effect of blood transfusions on the fate of kidney grafts is 
well recognized[l-3]. Recent retrospective clinical studies seem to indicate a link 
between blood transfusions and tumor growth in surgically treated patients[ 4,5]. 
Blood transfusion induced immunosuppression could be responsible for a 
detrimental outcome of patients with malignancies, due to promotion of tumor 
growth. However, anesthesia or surgery itself could be factors contributing to 
enhanced tumor growth. Anesthesia, the inseparable concomitant of surgical 
procedures, has also been implicated in the resulting decreased immune 
competence[l0-13]. Surgery, an important tool in the cancer therapeutic, arsenal, 
has been indicated as being immunosuppressive [6,7]. This has been subsequently 
substantiated by several in vitro studies demonstrating depression of cellular 
immunity following surgical procedures [8,9]. These immunological modulations 
following anesthesia, surgery and blood transfusion alone or surgery in 
combination with the others may also adversely effect tumor growth in cancer 
patients. 
We report here on the effects of anesthesia, abdominal surgery, blood 
transfusion alone or in combination on artifical metastatic growth, in a rat 
model. Furthermore,the influence of surgery and blood transfusions on take, 
homing, of circulating tumor cells is investigated. 
Material and methods 
Animals: Male rats of the inbred BN and WAG strains were used. The animals, 
aged 16-20 weeks, were bred under specific pathogen free conditions. 
Tumor: Tumor LS 175 is a spontaneous, non-immunogenic sarcoma in BN rats. 
The tumor is maintained as a stationary culture in Dulbecco's minimum essential 
medium, supplemented with 10% fetal calf serum (FCS). To obtain cells for the in 
vivo experiments, free floating LS 175 cell clumps were harvested from the tissue 
culture flasks and, after washing were resuspended in Hank's balanced salt 
solution (HESS). Single cells were prepared by rinsing the suspension through a 
pipette. Viability was assessed by trypan blue exclusion and was between 90 and 
95%. 
Lung colonies assay: 2.5 x lOS LS 175 tumor cells, suspended in a volume of 1 
ml, were injected intravenously into experimental and control rats. The number 
of colonies developing on the lungs were counted after 24 days. The lungs were 
excised, rinsed in tap water and subsequently fixed in Bouin's solution. Tumor 
nodules on the surface of both lungs, visible to the naked eye, were counted. 
Blood transfusions: BN rats received a single i.v. injection of 1 ml heparinized 
whole blood or 1 ml of syngeneic blood. Control animals received no transfusions. 
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Abdominal surgery: Under ether anesthesia, an ileum resection was performed 
of a 5-6 em segment, followed by end to end anastomoses using continuous 
suturing with 7.0 silk. The procedure lasted 15-20 minutes, with an estimated 
blood loss of ± 2 mi. 
Figure 1: Experimental design. 
TAKE 
DAYS 
GROWTH 
*No transfusion 
* Syngeneic blood transfusion 
* Allogeneic blood transfusion 
t 
-7 
Experimental design 
*No treatment 
*Surgery 
t 
0 +7 
• *No treatment 
*Ether anesthesia on days +7, +10, 
+14 and +17. 
*Syngeneic blood transfusion 
* Allogeneic blood transfusion 
*Surgery 
* Surgery + syng. blood transfusion 
* Surgery + allo. blood transfusion 
The effect of ether anesthesia on the growth of established metastases was 
investigated by anesthetizing a group of rats, inoculated with 2.5 x loS tumor 
cells on days 0, + 7, + 10, + 14, and + 17 for a period of 10 minutes (Figure 1). 
Control animals were injected with tumor cells on day 0 but did not undergo 
subsequent anesthesia. Each experimental group consisted of 8-12 animals. The 
effect on growth of artifical lung metastases of abdominal surgery alone, blood 
transfusion alone or the two in combination with each other, was studied. BN 
rats were injected with 2.5 x loS tumor cells i.v., on day 0. The control group 
received no further treatment. On day + 7 groups of tumor bearing rats received 
only syngeneic or allogeneic blood transfusions or additionally underwent 
abdominal surgery. One group underwent abdominal surgery and received no blood 
transfusion. The lung nodule assay, read on day + 29, was statistically analysed 
using the Student "t" test, the limit of significance being P<0.05. 
To study the take (homing) of circulating tumor cells, groups of BN rats 
received syngeneic or allogeneic blood transfusions on day -7 or underwent 
abdominal surgery on day 0. On day 0, animals were inoculated with 1 x 106 
tumor cells. Control animals received tumor cells on day 0 and did not undergo 
the experimental procedures on days -7 and 0. Survival times of these animals 
were monitered. 
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Table 1: Effect of blood transfusions; surgery; and surgery + blood transfusions 
on "growth" of tumor metastases. 
Transfusion on day +7 No. of Mean no. of 
animals lung colonies 
(+S.D.) 
No. transfusion/ surgery 12 13+4 
Syngen. transf. 10 17 + 6 
Allogen. transf. 10 26 +7 
Surgery 8 14+ 8 
Surgery+ syngen. transf. 10 14+4 
Surgery+ allogen. transf. 8 38 + 10 
Figure 2: Effect of blood transfusions on tumor "take". 
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Table 2: Effect of ether anesthesia on "growth" of artifical tumor metastases. 
Tumor inoculation No. of Mean no. of lung * 
on day 0 animals colonies (+S.D.) 
No treatment 15 35 + 22 
Anesthetized on days: 9 22+6 N.S. 
+ 7; + 10; + 14; + 17 
N.S.: not significant. 
Figure 3: Effect of surgery on tumor "take". 
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Results 
Certain experimental procedures on day + 7 had a profound effect on growth 
of established metastases, created by tumor inoculation on day 0 (Table 1). The 
mean number of lung nodules in the control group, on day +29, was 13 ± 4. 
Abdominal surgery, syngeneic blood transfusions alone and abdominal surgery in 
conjunction with syngeneic transfusion resulted in 14 ± 8, 17 ± 6 and 14 ± 4 
lung nodules, respectively. These numbers are not statistically different from the 
numbers found in the control group. The mean number of lung nodules in the 
group which received an allogeneic blood transfusion,was 26 ± 7, which is 
significantly higher than the number in the control group. Abdominal surgery in 
conjunction with allogeneic blood transfusion resulted in 38 ± 10 nodules, this 
also being statistically significantly higher with respect to the control group. 
Ether anesthesia on days + 7; + 10; + 14 and + 17 resulted in 22 ± 6 lung nodules, 
whilst the mean number of nodules of the control group was 35 ± 22(Table 2). 
These groups did not differ significantly from each other. 
The effect of blood transfusions and surgery on the take is illustrated in 
Figures 2 and 3. Animals receiving syngeneic or allogeneic transfusion on day -7 
showed a similar survival time to the control group(Figure 2). However, the 
survival time of animals which had undergone surgery on day 0 was significantly 
shorter than the control group(Figure 3), indicating a strong stimulating effect 
of surgery on "Take" of the circulating tumor cells. 
These results indicate no appreciable effect of ether anesthesia, surgical 
stress, syngeneic blood transfusion or a combination of the two on growth of 
artifical tumor metastases. Allogeneic blood transfusion alone or in combination 
with abdominal surgery elicited a significant enhancement of growth of artificial 
metastases. Blood transfusion had no effect on the "Take", although surgery 
resulted in a significantly enhanced homing of the circulating tumor cells. 
Discussion 
The retrospective data indicating a possible link between blood transfusion 
and poor prognosis for cancer patients[4,5] is compatible with results reported by 
Francis et al[14] and Marquet et al[15] in experimental animal models. They are 
also in accordance with the results in this report, showing that allogeneic blood 
transfusion leads to enhanced growth of tumor metastases (Table 1). Zeller et 
al[16] have reported either no effect or an inhibitory influence of blood 
transfusion, using different mouse strains and tumors. In a different tumor rat 
combination than the one used here, Jeekel et al[17] and Marquet et al[15] also 
found no effect of blood transfusion on growth of artifical tumor metastases. 
These reports strongly suggest that the blood transfusion effect is very much 
dependent on the properties of the tumor and host. Furthermore, the blood 
donor-acceptor combination may be an influential factor for the fmal outcome. 
The immunosuppresive effect of surgery is speculated to be of consequence 
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for therapeutic maneuvers in cancer patient treatment, as it may stimulate tumor 
growth. In the study presented, neither surgery alone nor surgery in combination 
with syngeneic transfusion was observed to have any effect on tumor growth 
(Table 1). However, surgery in combination with allogeneic blood transfusion 
resulted in significantly enhanced growth of tumor metastases. These results 
further support the above speculation. 
The possibility of an effect of anesthesia on the growth of metastases was 
addressed by Gaylord et al. in 1916[18]. They suggested an increased frequency 
of metastases following anesthetization, in a mouse tumor model. A profound 
effect on the immune apparatus resulting in effects like: transient leucopenia, 
decreased phagocytosis and mobilization of phagocytic cells, depression of B and 
T lymphocytes function, has been reported following anesthesia[10-13]. Ether 
anesthesia is reported to result in an increased number of metastases and a 
lower 5-year survival rate of breast cancer patients, when compared with 
halothane narcotized patients[19,20]. The ether anesthesia in our rat-tumor model 
did not demonstrate an adverse effect. Growth of artificial metastases was 
similar in control and ether narcotized animals. 
In contrast to the effect of allogeneic blood transfusion on growth of 
established metastases, no stimulating effect of syngeneic or allogeneic 
transfusion was observed on the take of tumor cells. Surgery was, however, 
found to enhance the take of the tumor cells. The reason for this difference may 
be that different factors are of importance in the processes of take and growth 
of a tumor cell, e.g.: NK cells may play a greater role in determining the process 
of take than growth[21,22]. The present study has demonstrated that allogeneic 
blood transfusion alone and in combination with surgery causes enhancement of 
tumor metastases growth. Whereas, surgery alone or combined with syngeneic 
transfusion, and ether anesthesia alone do not result in a significant acceleration 
of tumor growth. The take of circulating tumor cells does not seem to be 
influenced by blood transfusions on day -7; abdominal surgery, on day 0, seems 
to have a stimulatory effect. In view of previous clinical and experimental 
reports, the significance of this observed alteration metastases growth and take 
of tumor cells could be of far reaching importance in clinical practice. 
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CHAPTER6 
ENHANCED GROWTH OF ARTIFICIAL TUMOR METASTASES FOLLOWING BLOOD 
TRANSFUSION: 
The effect of erythrocytes, leukocytes and plasma transfusion. 
This chapter was published in Europ. J Cancer and Clin. Oncology 1987; 23:1537-
1540. 
Summary 
Allogeneic blood transfusions have been shown to modulate tumor growth in 
different ways, depending on the tumor-host models used in the studies. 
Previously, we have demonstrated the enhanced growth of artificial tumor 
metastases following allogeneic whole blood transfusion, in a BN rat-LS 175 
tumor model. In experiments reported here, we have investigated the effect of 
transfusion of different blood components on the growth of tumor metastases. 
Erythrocytes and leukocytes are found to promote the growth of LS 175 tumor 
metastases in BN rats. A similar effect is observed following whole blood 
transfusion. Plasma transfusion did not have a effect on tumor growth in this 
tumor-host model. 
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Introduction 
Clinical and experimental results have shown a prolongation of renal allograft 
survival, following pre-operative blood transfusions[l-4]. Investigations into which 
blood components could be responsible for the immuno-suppression after blood 
transfusions have produced conflicting results. Lymphocytes, erythrocytes and 
platelets have been shown to be effective by some[5-9], while others were unable 
to replicate these results [10]. Recent retrospective studies have indicated a link 
between blood transfusion and shorter disease free interval of cancer patients 
[11,12]. Employing different host-tumor models, experimental studies have shown 
reduced, stimulated or no effect on tumor growth following blood 
transfusions[13,14]. Previously, we have demonstrated enhanced growth of 
artifical tumor metastases following allogeneic whole blood transfusion, in a rat 
tumor model[l5,16]. 
In the experiments reported here, we have investigated the competence of 
different components of blood in modulating metastatic growth. Effect of 
erythrocytes, leukocytes and plasma transfusion on tumor growth is compared 
with the effect observed after transfusion of whole blood. 
Material and methods 
Animals: Male rats of the inbred BN and WAG strains were used. The animals 
aged 16-20 weeks, were bred under specific pathogen free conditions. 
Tumor: Tumor LS 175 is a spontaneous, non-immunogenic sarcoma in BN rats. 
The tumor is maintained as a stationary culture in Dulbecca's minimum essential 
medium, supplemented with 10% fetal calf serum (FCS). To obtain cells for the in 
vivo experiments, free floating LS 175 cell clumps were harvested from the tissue 
culture flasks and, after washing were resuspended in Hank's balanced salt 
solution (HBSS). Single cells were prepared by rinsing the suspension through a 
pipette. Viability was assessed by trypan blue exclusion and was between 90 and 
95%. 
Lung colonies assay: 2.5 x loS tumor cells, suspended in a volume of 1 ml, 
were injected intravenously into experimental and control rats. The number of 
colonies developing on lungs were counted after 24 days. The lungs were excised, 
rinsed in tap water and subsequently flXed in Bouin's solution. Tumor nodules on 
the lung surface, visible to the naked eye, were counted. 
TRANSFUSIONS: 
Whole blood: BN rats received a single i.v. injection of 1 ml heparinized whole 
blood. 
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Erythrocytes: Heparinized WAG rat whole blood was centrifuged for 10 minutes 
at 200 x g, the buffy coat removed and the sediments were pooled and passed 
in HESS over a cotton wool column, as described by Diepenhorst et al[17]. BN 
rats received an i.v. injection of an equivalent number of erythrocytes present in 
1 ml whole blood (5 x 109), suspended in a volume of lml of HESS. This 
suspension was contaminated with < 1% leukocytes found in normal blood. 
Leukocytes: Whole blood was diluted 1:2 with HESS. Leukocytes were obtained 
by centrifuging diluted blood into lymphocyte separation medium (LSM;Bionetics). 
Residual erythrocytes were eliminated by three successive incubations of the 
leukocyte enriched suspension, with hemolytic buffer (tris-buffered ammonium 
chloride 0.17M) and subsequently washed in HESS. This procedure resulted in 
marked reduction in the number of erythrocytes ( <0.1%). The viability of the 
remaining leukocytes was determined by the trypan blue exclusion test, and 
appeared to be >95%. About 1 x 107 /mlleukocytes, equivalent to the number of 
cells in 1 ml of whole blood, were suspended in HESS and 1 ml of the suspension 
was administered i.v. to BN rats. 
Plasma: Heparinized WAG rat whole blood was centrifuged for 10 minutes at 
1500 x g and the resulting supernatant collected. The supernatant was 
subsequently passed through a filter of 0.45 JJ-m gauze (schleicher & schull; 
FP030/2). Half a milliliter of the ftltered plasma was administered i.v. to BN rats. 
Experimental design 
Blood constituents responsible for the stimulation of tumor metastatic growth 
were investigated. BN rats were inoculated with 2.5 x lOS LS 175 tumor cells, on 
day 0. On day + 7 groups of rats received i.v. 1 ml of either whole WAG rat 
blood or WAG erythrocyte suspension, leukocyte suspension, or 0.5 ml of plasma, 
respectively. Control animals were not transfused. The animals were sacrificed on 
day + 24 and a lung colony assay was performed. The assay was statistically 
analysed using Student "t" test, with limit of significance P<0.05. 
Results 
The resulting· colonies on the lung surface on day + 24 following experimental 
procedures on day + 7, are illustrated in Table 1. The mean number of lung 
colonies in the group of animals administered whole blood was 68 ± 7. Animals 
which did not receive any treatment, the control group, had 17 ± 6 lung 
colonies. Hence, the number of colonies found in the control group is 
significantly less than animals transfused with whole blood. Groups of animals 
administered erythrocyte and leukocyte suspension demonstrated mean numbers of 
colonies of 57 ± 2 and 68 ± 8, respectively. These numbers are also statistically 
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Table 1: Effect of whole blood, leukocytes and erythrocytes on the growth of 
established tumor metastases. 
Transfusion on day +7 Number of animals Mean number of lung colonies 
Washed leukocytes 9 68± 8 
Washed erythrocytes 10 57 ±2 
Whole blood 10 68 ± 7 ··:·=·:.·.:··::-·: .... :.·:.·:.·:.·.·=·:::.-.·::-·.· .. ;·.·.·.;:·:····:::::. 
No transfusion 10 17 ± 6 
Table 2: Effect of plasma transfusion on growth of established tumor metastases. 
Transfusion on day +7 Number of animals Mean number of lung colonies 
Plasma 10 53± 11 ~ 
No transfusion 9 54± 12 
~-------------------" 
significantly higher than found in control animals. The numbers found in the 
experimental groups were similar to one another. 
The group of animals receiving plasma transfusion had 53 ± 11 lung 
colonies(Table 2). The control group of the plasma transfused animals, which did 
not receive any transfusion, had 54 ± 12 lung colonies i.e.: there was no 
difference between these groups. 
Discussion 
Different blood components have been shown to be successful in the 
attainment of effective immunosuppression in organ transplant models[5-8]. 
Jenkins et al[10] have been able to achieve prolongation of cardiac allografts in 
rats by lymphocyte transfusates, but were unable to obtain the same effect by an 
erythrocyte transfusion. J eekel et al[ 5] found that a purified donor erythrocyte 
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transfusion was capable of inducing indefinite survival of rat kidney allografts. 
Francis et al[13] have demonstrated stimulated tumor growth and depressed 
lymphocyte reactivity in laboratory animals, following whole blood transfusion. 
We have shown similarly reduced immunocompetence and metastatic growth[16,18]. 
The blood donor WAG rat differs for class I and class II antigens, with respect 
to the BN tumor bearing rats. Erythrocytes in the rat express class I 
histocompatibility antigens of the A locus at the cell surface but do not express 
any detectable class II antigenic determinants (B and D locus products). 
Leukocytes express both class I and class II antigens. Erythrocyte and leukocyte 
suspensions were equally efficient in stimulating tumor growth as did the whole 
blood transfusion. This suggests that class I antigens alone or combined with 
class II antigens is capable of producing the blood transfusion effect observed 
here. The small degree of leukocyte contamination of the erythrocyte suspension 
might explain the observed effect of the erythrocyte transfusion. However, Wood 
et al[19] have also shown suppression of the immune apparatus following 
transfusion with a highly purified erythrocyte suspension. Kapnick et al[8] have 
shown that a platelet transfusion, which also lack class II antigens, is also 
capable of inducing unresponsiveness to skin allografts in mice. In a study of a 
host-tumor model where allogeneic whole blood transfusion resulted in reduced 
tumor growth, Oikawa et al.[20] observed a similar effect following 
administration of red blood cell, leukocyte and platelet transfusions. This 
observation and our results here suggest that different blood components are 
capable of producing similar results to those obtained following whole blood i.v. 
transfusion, in a particular host-tumor model. In analyses of the retrospective 
data of surgically treated cancer patients, Blumberg et al.[12] found a 
relationship between the greater amount of blood and blood component transfused 
and a higher incidence of recurrence and death. One explanation could be the 
presence in plasma of a substance capable of reducing immune function in the 
transfused patients. Margolese et al.[21] have demonstrated a poor response of 
breast cancer patients' lymphocytes to T cell growth factor, in the presence of 
viruses. Furthermore, growth of transplanted tumors in mice is shown to be 
greatly enhanced following plasma transfusion[22]. Francis et a1.[13] have also 
reported an increase in plasma suppressive activity after allogeneic transfusion 
and not following syngeneic or saline infusion in rats. However, our results do 
not support the hypothesis of the presence of a substance capable of modulating 
tumor growth. 
To summarize, erythrocyte and leukocyte transfusions are capable of 
producing enhanced growth of tumor metastases, the effect being similar to that 
of whole blood transfusion. Plasma transfusion has no effect on tumor growth. 
Class II antigens do not appear to be a crucial factor in precipitating the blood 
transfusion effect, since the same effect was observed after transfusion of 
erythrocytes bearing only Class I antigens. 
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CHAPTER7 
EFFECT OF SURGERY AND BLOOD TRANSFUSION ON IMMUNE PARAMETERS 
IN A RAT MODEL. 
NATURAL KILLER CELL ACTIVITY; GAMMA INTERFERON PRODUCTION 
CAPACITY; MITOGEN STIMULATION; LEUKOCYTE PHAGOCYTIC ACTIVITY. 
This chapter has been submitted for publication. 
Summary 
Allogeneic blood transfusion alone and in combination with abdominal surgery 
was found to have a strong positive effect on the growth of the tumor 
metastases. Surgery alone did not demonstrate this effect( chapter 5). Following 
blood transfusions and surgery alone and in combination, immune parameters like 
Natural killer cell activity; Gamma Interferon Production Capacity; T-lymphocyte 
mitogen blastogenic stimulation; and circulating leukocyte phagocytic capacity 
were monitored. A correlation between decreased mitogen blastogenic stimulation 
and increased tumor growth is observed, indicating a role of T-lymphocytes in 
this blood transfusion phenomenon. This is indirectly supported by the increased 
tumor growth observed following cyclosporin treatment. Other immune parameters 
did not show a correlation with modified tumor growth. The immune status of 
the local environment of the metastases may provide crucial information for 
understanding this phenomenon. 
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Introduction 
The concept that pretransplant blood transfusion improves the outcome of 
kidney grafts is now widely accepted [1-3], although there is no consensus 
regarding the mechanism for this phenomenon. A suppressed immune-response is 
generally considered to be the path leading to better graft survival. Francis et al 
and our group have demonstrated that allogeneic blood transfusion has an 
enhancing effect on tumor growth in certain animal models[ 4,5]. A number of in 
vitro studies have confirmed the presence of post-transfusion immunosuppression 
[6,7]. Surgery, an important tool in the cancer therapeutic arsenal, has been 
indicated as being immunosuppressive [8,9]. This has since been substantiated by 
several in vitro studies demonstrating depression of cellular immunity following 
surgical procedures[10,11]. Immunological modulation following surgery in 
combination with blood transfusion may be a contributing factor in adversely 
affecting tumor growth in cancer patients. 
Cyclosporin A(Cy A) is a fungal metabolite and the first of a new generation 
of immunosuppressive agents with a specilic site of action within the immune 
system. The mechanism of action of Cy A is not fully understood but it appears 
to affect T-cells at an early stage in their transformation[12,13]. Gordon and 
Singer have suggested that a sub-population of T-cells is particularly susceptible 
to the drug[14]. Eccles et al. have demonstrated a greatly increased metastasis of 
lymphomas and sarcomas in a rodents-tumor model, following Cy A treatment[15]. 
Cyclosporin A offers the possibility of studing the modulation of tumor growth in 
syngeneic hosts, subjected to specilic immune suppression. 
Here we report the results of in vitro tests performed to quantitate the 
immuno-modulating effects following the experimental procedures: surgery alone, 
blood transfusion alone or the two procedures in conjunction. The immune status 
of the animals was determined by the following parameters: Natural Killer cell 
(NK) activity; Gamma- Interferon Production Capacity (GIPCA); leukocyte 
phagocytic capacity and PHA and Con A mitogen blastogenic response. 
Furthermore, the drug cyclosporin is used to investigate the validity of the 
proposed correlation between tumor growth and T -cell function. 
Material and methods 
Animals: Male rats of the inbred BN and WAG strains were used. The animals, 
aged 16-20 weeks, were bred under specilic pathogen free conditions. 
Tumor: Tumor LS 175 is a spontaneous, non-immunogenic sarcoma in BN rats. 
The tumor is maintained as a stationary culture in Dulbecco's minimum essential 
medium, supplemented with 10% fetal calf serum (FCS). To obtain cells for the in 
vivo experiments free floating LS 175 cell clumps were harvested from the tissue 
culture flasks and, after washing were resuspended in Hank's balanced salt 
solution (HESS). Single cells were prepared by rinsing the suspension through a 
pipette. Viability was assessed by trypan blue exclusion and was between 90 and 
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95%. 
Blood transfusions: BN rats received a single i.v. injection of 1 ml heparinized 
whole allogeneic blood or 1 ml of syngeneic blood. Control animals received no 
transfusions. 
Adominal surgery: Under ether anesthesia, an ileum resection of a 5-6 em 
segment was performed followed by end-to-end anastomoses using continuous 
suturing with 7.0 silk. The procedure lasted 15-20 minutes, with an estimated 
blood loss of ± 2 ml. 
Cyclosporine : Cyclosporin dissolved in olive oil was administered in a dose of 
5mg/Kgi.m .. 
Lung colonies assay: 2.5 X lOS tumor cells, suspended in a volume of 1 ml, 
were injected intravenously into experimental and control rats. The number of 
colonies developing on lungs were counted after 24 days. The lungs were excised, 
rinsed in tap water and subsequently fixed in Bonin's solution. Tumor nodules on 
the lung surface, visible to the naked eye, were counted. 
NK Cell assay: 
Lymphocyte cell preparation: 
The spleens from rats were cut into fragments and pressed through a 100 m 
sieve. Lymphocytes were isolated using a Ficoll Isopaque gradient, washed and 
resuspended with 5 ml RPMI containing 10% FCS and incubated for 1 hour at 
37°C in tissue culture flasks. Thereafter, the cell suspension was adjusted to a 
concentration of 20 x 106 living cells per ml. 
Chromium (51Cr) release assay for NK cell activity: 
Natural cytotoxicity was measured in a 4-hr assay using 51Cr labeled YAC 
target cells [16,17]. Two million target cells were incubated with 400JLCi of Na2 51Cr04 solution (specific activity 50-400,JLCifmg 51Cr; Amersham, U.K.) for 1 hr 
at 3~C. The 51Cr labeled targets wen~ washed twice, counted and resuspended 
at a concentration of <0.1 x 106 per ml. All assays were performed in triplicate 
in round-bottomed microtiter plates (Nunc, Denmark) in a total volume of 0.2 ml 
of RPMI 1640 supplemented with 10% FCS. In all assays, 1 x 104 targets were 
added to each well. Lymphocyte effector cells were added at various 
concentrations according to the chosen lymphocyte-to-target cell ratio 25:1, 50:1, 
100:1 and 200:1 respectively. The microtiter plates were centrifuged for 3 minutes 
at 150 x g and then incubated for 4 hr at 3~C in a humidified 5% C02 
incubator. To harvest the assay, plates were centrifuged for 1 minute at 150xg 
and the supernatants were removed using the method described by Hirschberg et 
al[18]. The release of 51Cr was determined by counting radioactivity in a gamma 
counter (LKB Wallace Ultragamma II (280). 
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Specific cytotoxicity: 
The percentage specific lysis m all experiments was calculated according to 
the formula: 
mean exp. release - mean spontaneous release 
% Specific lysis = x100 
mean max. release - mean spontaneous release 
The maximum release was calculated by adding 10% cetavlon (ICI UK) to an 
aliquot of target cells. Spontaneous release was defined as the 51Cr released 
from target cells incubated with medium alone. This value was usually 6-10% of 
the maximum. Mean counts and standard deviation were determined in triplicate 
tests. 
Max % specific lysis was obtained with a lymphocyte-to-target cell ratio of 
100:1 and thus only these results are reported here. The percentage specific lysis 
of the control group is taken as 100% and other results are expressed as % 
relative to the control group. 
Concanavalin A induced gamma inteiferon production capacity (GIPCA): 
Lymphocytes were suspended at 1x106 cells per m1 RPMI 1640 containing 10% 
FCS, 50 I.U. penicillin, 50 Ji. g streptomycin, 2 mM L-glutamine and 10-5M 
2-mercaptoethanol. 1 ml of this cell suspension was supplemented with 7.5 g 
Con A and incubated for 3 days at 37°C in a 5% Co2 humidified atmosphere. The 
supernatant from each culture was then harvested and the anti-viral activity 
determined by the inhibition of the cytopathogenic reduction assay by a dye 
uptake method using Ratec cells and 100 TCID 50 vesicular stomatitis virus as 
challenge. GIPCA of the control group is taken as 100% and GIPCA of the 
experimental groups are expressed as % relative to the value of the control 
group. 
PHA and CON A stimulation assay: 
Lymphocyte concentration was adjusted to 7.5 x 106 cells per ml in RPMI 
1640 medium containing 10% FCS. Cultures of 200 1 containing 1JJ.g PHA-P 
(Wellcome, UK) and 1JJ.g Con A respectively were maintained for 3 days at 37°C 
in a 5% C02 humidified incubator. Six hrs prior to termination, each culture was 
labeled with 0.8JJ.Ci of methyl-3-H-thymidine eH-Tdr, specific activity 2Ci/mmol; 
Amersham, UK). After a period of 6 hrs, cultures were harvested with an 
automatic harvester (microtiter-automash, Dynatech, Holland). Cells were 
collected on fiber glass filters and after drying, the filters were placed in 
scintillation vials, 3 ml scintillation fluid added and uptake of 3H-Tdr determined 
with a liquid scintillation counter (B, searl isocap II; efficiency 96%). 3H-Tdr 
uptake by the control group was equated to 100 % and the values of other 
groups were expressed as relative response to the control value. 
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Phagocyte activity of leukocytes: 
Peripheral blood was obtained by cardiac puncture and 2 ml of blood was 
mixed with an equal volume of Plasmasteril(R) (Fresenius, Bad Romberg, FGR). 
The mixture was incubated at 37JC for one hr after which the leukocyte-rich 
supernatant was collected and washed twice in HESS. The fmal leukocyte 
suspension was adjusted at 5 x 106 leukocytes/mi. The phagocyte assay was 
performed in triplicate in 12.5 ml round-bottomed glass tubes by mixing 0.05 ml 
of the leukocyte suspension with 0.05 m1 of a suspension containing 5x108 /ml 
carboxylated microspheres of diameter 1.74 (Polysciences Inc.,Warrington, PA, 
USA). The tubes were incubated for 1 hr at 37°C in a gently shaking water 
bath. The leukocytes were then stained with crista! violet dye after which the 
degree of phagocytosis was determined in a hemocytometer chamber. By counting 
two hundred leukocytes, the percentage of phagocytic cells and the average 
number of ingested microspheres per phagocytic cell was calculated. By 
multiplying these two numbers a phagocytic index (=number of ingested 
microspheres per 100 leukocytes) was obtained. The index was used to determine 
whether there was a significant difference between experimental and control 
values. 
Experimental design 
A: An assessment was carried out of immuno-parameters of the control and 
experimental groups. Following tumor inoculation on day 0, animals received 
syngeneic or allogeneic blood transfusion, underwent abdominal surgery alone or 
in conjunction with blood transfusion, on day + 7. Immuno-parameters were 
determined on days + 8, + 11 and + 15. Parameters assessed were NK activity; 
-interferon production capacity (GIPCA); leukocyte phagocytic capacity and; PHA 
and Con A mitogen stimulation response capacity. Each group comprised 5 
animals. Naive animals, n=5, were taken as a control group for each experimental 
group. The statistical significance was determined by the Student "t" test with 
limit of significance p < 0.05. 
Immune-parameters of naive BN rats were compared with parameters of BN 
rats bearing tumor metastases, over the period day 0 to + 15 post-tumor 
inoculation. No differences in the values were found (data not shown) and thus 
parameters of naive rats were taken as control values in subsequent result 
analyses. The results of the different experimental groups were made comparable 
by expressing them in terms of relative responses index, taking the values of 
naive control BN rats as 100%. 
B: On day 0 BN rats were inoculated with 2.5xloS LS 175 tumor cells. 
Control animals received no further treatment. On days +7, +10 and +14, the 
experimental animals received cyclosporine in a dose of 5mg/Kg i.m. All animals 
were sacrificed on day + 28 and sebsequently a lung colonies assay was performed. 
The results were statistically tested by the Student "t" test with limit of 
significance p < 0.05. 
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Figure 1: Effect of blood transfusion and surgery on NK-cell activity. 
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Figure 2: Effect of blood transfusion and surgery on Con-A T -cell stimulation 
test. 
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Table 1: Immune parameters expressed as relative response index. 
Days N.K. 
Syngeneic transfusion + 8 80 
+11 96 
+ 15 119 
Allogeneic transfusion + 8 106 
+11 76 
+ 15 (176) 
Abdominal surgery + 8 (309) 
+11 (223) 
+ 15 (214) 
Abdominal surgery + + 8 133 
syngeneic transfusion +11 102 
+ 15 (145) 
Abdominal surgery + + 8 (173) 
allogeneic transfusion +11 66 
+ 15 (238) 
(X): statistically significant from control group. 
nd: not done. 
Key to figures 1-4: 
Group I : Syngeneic transfusion on day + 7. 
Group II : Allogeneic transfusion on day + 7. 
Group lli :Abdominal surgery on day + 7. 
Con A PHA 
( 79) nd 
86 . 69 
(78) (58) 
(19) 70 
(31) ( 64) 
(53) (194) 
(211) 87 
(52) 85 
(62) 93 
93 
(74) 47 
(63) (27) 
(26) 90 
(29) (48) 
(56) 334 
Group IV : Abdominal surgery + syngeneic transfusion on day + 7. 
Group V : Abdominal surgery + allogeneic transfusion on day + 7. 
Results 
Gipca 
74 
65 
47 
(164) 
(210) 
122 
nd 
nd 
nd 
68 
46 
50 
102 
130 
163 
A: Immune parameters following abdominal surgery and blood tramsfusion 
LPC 
N 
N 
N 
(l) 
N 
(T) 
(T) 
(T) 
(T) 
(T) 
(T) 
(T) 
(T) 
(T) 
(T) 
Immune parameters were determined to evaluate the effect of blood 
transfusion, abdominal surgery and a combination of the two procedures on the 
immune system in artificial micrometastases-bearing BN rats. BN rats were 
inoculated with tumor cells on day 0. On day + 7 animals received syngeneic or 
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Figure 3: Effect of blood transfusion and surgery on PHA T -cell stimulation test.. 
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Figure 4: Effcet of blood transfusion and surgery on gamma-interferon production 
capacity assay (GIPCA). 
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allogeneic blood transfusion alone or additionally underwent abdominal surgery. 
One group underwent abdominal surgery and received no transfusion. 
Immuneparameters on days + 8, + 11 and + 15 were subsequently determined. 
NK-cell activity: 
Syngeneic blood (group 1) transfusion had no effect on NK cell activity 
(Table 1, Figure 1). A significant increase of NK cell activity was observed, 8 
days after administration of allogeneic blood (group II). Abdominal surgery (group 
III) resulted in a marked increase of NK cell response one day after surgery and 
remained significantly above control values for a period of 8 days. Surgery in 
conjuction with syngeneic blood transfusion (group IV) also resulted in an 
elevation of NK response, but this occured at a much later stage, i.e.: 8 days 
post -surgery. Surgery in conjunction with allogeneic transfusion (group V) 
showed a significantly higher NK cell response on the 1st day following the 
experimental procedure: this was normal by the 4th day and was significantly 
higher again on the 8th day. The results indicate an increase in NK cell activity 
following allogeneic transfusion and abdominal surgery. Surgery in conjunction 
with allogeneic blood transfusion also tends to show a higher response with a 
transitional drop at 4 days. 
Mitogen response: 
The mitogen response was significantly reduced or normal, in all experimental 
groups (Table 1, Figure 2 and 3). The response to Con A and PHA of syngeneic 
transfused rats was significantly lower on the 1st day after transfusion, but 
returned to normal by the 4th day and dropped again on the gth day. 
Allogeneically transfused rats showed a significantly lower response to Con A 
throughout the follow up period. In these rats, the response to PHA on the 1st 
day after transfusion was normal but became significantly reduced on the 4th day 
and then significantly higher than normal on the gth day following transfusion. 
Abdominal surgery alone and in conjunction with syngeneic or allogeneic 
transfusion led to a normal response to PHA stimulation, with only a 
transitional decrease in responses on the 4th day following allogeneic transfusion 
and the gth day after syngeneic transfusion. However, one day after abdominal 
surgery a significantly stronger response to Con A (relative response index of 
211) was observed with subsequent significantly lower responses 4 and 8 days 
after surgery. Surgery in combination with syngeneic and allogeneic blood 
transfusion demonstrated a significantly lower response to Con A, throughout the 
observation period. Furthermore, the response in the group surgery + allogeneic 
transfusion overall was lower than the group surgery + syngeneic transfusion 
(Table 1). 
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GIPCA: 
The gamma-interferon production capacity (GIPCA) of animals administered 
syngeneic transfusion alone or in conjunction with surgery was comparable to 
the GIPCA of control rats(Table 1, Figure 4). Allogeneic blood transfused rats 
displayed a significantly stronger GIPCA on the 1st and 4th days after 
transfusion, with relative response indices of 164 and 210, respectively. On the 
gth day after transfusion, the GIPCA response returned to normal. The group 
receiving syngeneic or allogeneic transfusions in addition to abdominal surgery 
showed GIPCA values similar to the control group. Thus, except for a slight 
increase in GIPCA following allogeneic transfusion, no other experimental 
procedure affected this parameter. 
Phagocytosis: 
Following allogeneic transfusion, a significant drop in leukocyte phagocytic 
capacity was observed. It returned to normal on the 4th day after transfusion 
and then became significantly higher by the gth day (Table 1). Following 
abdominal surgery, alone or in combination with syngeneic or allogeneic 
transfusion, a significantly elevated phagocytic capacity was encountered 
throughout the follow up period. 
Table 2: Effect of cyclosporine A on growth of established metastases. 
Tumor inoculation 
on day 0 
No treatment 
Cyclosporine-A 
(5 mg/kg/doses, i.m.) 
on days: + 7; + 10; + 14 
*: Statistically significant. 
No. of 
animals 
10 
9 
B: The effect of cyclosporine on tumor growth. 
Mean no. of lung 
colonies (+S.D.) 
17 + 6 
60 + 12* 
The results of the experimental animals are illustrated in Table 2. In control 
animals, 17 ± 6 lung colonies were found on the lung surface, whereas the Cy A 
treated group had 60 ± 12 colonies. The number of colonies in the Cy A treated 
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group was significantly higher than in the control group, P < 0.001 according to 
the Student "t" test. 
Discussion 
NK cells are believed to have an important role in immune surveillance and 
inhibition of growth of tumors. High NK cell activity in vitro has been reported 
to correlate with resistance to tumor growth in experimental models [19,20]. 
Furthermore, a low NK cell response has been reported in lymphoma patients[21]. 
In the present study, we found no such correlation between NK cell response and 
metastatic growth, as reported in chapter 5. Fodstad et al[22] have reported a 
similar lack of correlation in mouse experiments. This may indicate a relatively 
minor, if any, role of NK cells in determining the growth of established artifical 
metastases, in our model. 
Reticulo-endothelial(R.E.) phagocytic activity has been reported to be 
profoundly diminished following surgical stress[23]. We measured the phagocytic 
capacity of the circulating leukocytes, which play an important role in the 
overall defence mechanisms of an organism[24,25]. However, in contrast to the 
effect on the phagocytosis capacity of R.E., a significant increase was observed 
in the phagocytic activity of circulating leukocytes following surgery alone or in 
combination with blood transfusion. Similar results are reported in the post-
operative period in patients undergoing surgery[26]. No exact mechanism for 
these observations is known. The mitogen blastogenic response has been reported 
to be diminished following blood transfusion[6,7] and surgery[27]. Francis et al[5] 
have shown a significant decrease in lymphocyte reactivity and increased tumor 
growth in animals which had received an allogeneic blood transfusion. The results 
given in Table 1 demonstrate a statistically significant depression of blastogenic 
response following blood transfusion, surgery alone or surgery in combination 
with blood transfusion. Furthermore, a greater decrease in response is observed 
in animals administered allogeneic transfusion alone or allogeneic transfusion in 
conjunction with surgery. This is compatable with the observed increase in the 
growth of tumor metastases (chapter 5). The number of colonies in the Cy A-
treated group was significantly higher than in the control group. These results 
further substantiate a possible role ofT -cells in the modulation of tumor growth. 
Although the downward trend of response is similar for Con A and PHA 
stimulation, the results (Table 1) show some differences between the responses of 
the two mitogens. A possible explanation for these differences could be the fact 
that Con A stimulates T-lymphocytes, while PHA stimulates predominantly 
T-lymphocytes but also B-lymphocytes to a certain extent. 
There is yet no concordance about the role of interferon in the defence 
against tumors. Interferon has been reported to be capable of increasing the 
lethal effect on tumor cells, by NK cell and macrophage stimulation[28]; 
therefore, following the experimental procedures, GIPCA was performed. No 
correlation was found between GIPCA and the observed growth of tumor 
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metastases after the experimental procedures. A similar lack of correlation has 
been reported by Moiler-Larsen et al[29]. Furthermore, the GIPCA test employed 
here is more sensitive to measure an increase rather than a depression in 
interferon production. This could be an explanation for the discrepancy in the 
depressed mitogen stimulation response and the absence of changes in GIPCA 
values. 
To summarize, only mitogen blastogenic responses seemed to be important 
parameters with respect to the enhanced tumor growth by blood transfusions, 
indicating a predominant role for T -cells in this phenomenon. However, all 
parameters were determined for peripheral blood and spleen lymphocytes, factors 
present locally in the area of the metastases may be of paramount importance. 
There is a great need for further investigation of the local factors and 
elucidation of the mechanism underlying the observed effects. 
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CHAPTERS 
ARE GROWTH FACTORS INVOLVED IN THE BLOOD TRANSFUSION PHENOMENON? 
Summary 
Allogeneic blood transfusions are shown to be capable of modifying tumor 
growth. We have previously demonstrated a correlation between modified tumor 
growth and the T -cell function of transfused animals. Recently, several cytokines 
have been shown to affect the function of many different immune competent 
cells. We hypothesized that growth factor(s) might be induced by allogeneic 
transfusion. The validity of this suggestion was tested by assaying the growth of 
tumor cells in vitro. The results of this experiment do not support the 
speculation of an important role of growth factors in the blood transfusion 
phenomenon. 
61 
Introduction 
The beneficial effect of pre-transplant blood transfusion on organ transplant 
survival is a generally accepted fact. However, the underlying mechanism has 
remained elusive. Several hypotheses e.g.: clonal deletion, anti-idiotypic and 
suppressor T -cells, have found supportive evidence from clinical and experimental 
studies[1-3]. All these mechanisms envisage a predominant role ofT-cell function. 
The effect of blood transfusion on tumor growth has been reported in chapters 4 
and 5. In this blood transfusion effect, a correlation with T -cell function has 
also been demonstrated [chapter 7]. 
In recent years, increasing numbers of cytokines have been isolated. Cytokines 
are thought to be the mode of communication between different cells and have 
been shown to affect the functioning of different cells in vivo. Murine virus-
transformed sarcoma cells have been shown to secrete transforming growth 
factors, which strongly stimulate soft agar colony formation[4]. Activated 
mononuclear cells produce Interleukin I (ILt) which is capable of fibroblast 
proliferation[ 5]. Platelet -derived growth factors and platelet -derived angio-genesis 
factor are found to be potent mitogen- and chemoattractants[6,7]. Macrophages 
from ovarian, breast, colon, or lung adeno-carcinomas have been demonstrated to 
secrete soluble factor(s), capable of enhancing colony formation of human tumor 
cell lines[8]. Many more cytokines with a variety of cell function modulating 
properties have been isolated. 
We hypothesized that allogeneic blood transfusion could form a trigger for the 
release or production of systemic factor(s), which directly or indirectly modify 
the functioning of immunological and tumor cells. This then could result in an 
immunosuppresive state leading to better organ transplantion survival or, in 
cancer patients to enhanced tumor growth. In this communication we report the 
results of an in vitro study to verify this hypothesis. 
Material and methods 
Aninals: Male rats of the inbred BN and WAG strains were used. The animals, 
aged 16-20 weeks, were bred under specific pathogen free conditions. 
Tumor: Tumor LS 175 is a spontaneous, non-immunogenic sarcoma in BN rats. 
The tumor is maintained as a stationary culture in Dulbecco's minimum essential 
medium, supplemented with 10% fetal calf serum (FCS). To obtain cells for the in 
vivo experiments, free floating LS 175 cell clumps were harvested from the tissue 
culture flasks and, after washing, were resuspended in Hank's balanced salt 
solution (HESS). Single cells were prepared by rinsing the suspension through a 
pipette. Viability was assessed by trypan blue exclusion and was between 90 and 
95%. 
Bood transfusions: BN rats received a single i.v. injection of 1 ml heparinized 
whole WAG blood or 1 ml of syngeneic blood. Control animals received no 
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Figure 1: Growth rate of tumor cells m serum obtained one day after blood 
transfusion. 
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Figure 2: Growth rate of tumor cells in serum obtained four days after blood 
transfusion. 
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transfusions. 
Tumor cell growth assay: LS 175 tumor cells were suspended at 5X103 cells per 
ml in RPMI 1640, containing 5% rat serum (from normal or experimental animals), 
1% penicillin and streptomycin and 1% L-glutamine. Two ml of this cell 
suspension was incubated in flat bottomed titer plates at 31lC in a 5% C02 
humidified incubator. On days 3 to 7 after incubation, the mean number of tumor 
cells per well was determined in triplicate. 
Experimental protocol 
Growth rate of tumor cells in the serum of transfused BN rats was assessed 
and compared to that in normal BN rat serum. A group of animals received 
allogeneic or syngeneic blood transfusion 7 days after tumor cell inoculation. On 
days + 8, + 11 and + 15, animals were sacrificed and serum obtained from the 
peripheral blood. Tumor cell growth rate assay was performed, utilizing serum 
from the different experimental groups. Normal BN rat serum was used as 
control. The statistical significance was assessed by Student "t" test, with limit 
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Results 
The proliferation rates of tumor cells incubated with serum of blood 
transfused rats is illustrated in Figures 1-3. The growth rate of tumor cells 
incubated in serum of rats transfused one day previously is similar to the cells 
incubated with serum of normal BN rats. Allogeneically or syngeneically 
transfused rat serum did not show any difference in the effect on tumor 
cells(Figure 1). No difference was found in growth rate of cells incubated in the 
serum of BN rats transfused 4 or 8 days previously(Figure 2 and 3). Statistically 
significant differences were never observed. 
Discussion 
Enhanced tumor growth is observed following immunosuppresive procedures 
e.g.: multiple operations[9]. Constantian et al have demonstrated that the 
immunosuppresive effect of operative and accidental trauma is correlated with 
the presence of a polypeptide in the serum of these patients[10]. Peripheral blood 
lymphocytes of patients with advanced breast cancer are shown to be inhibited 
in their response to mitogenic stimuli. This suppressive effect on lymphocytes is 
abrogated by addition of T-cell growth factor (TCGF) to these lymphocytes in 
culture[ll]. In our experiments, no difference in growth rate was found between 
tumor cells incubated in normal rat serum or serum from syngeneically or 
allogeneically transfused rats. This seems to indicate a lack of presence of extra 
growth factors in the serum of transfused rats. Furthermore, preliminary results 
of a study of the effect of a known platelet growth factor, in the same 
experimental settings as used above, also indicate no effect on the tumor growth 
rate. These results would seem to indicate that growth factors are not important 
for the rate of tumor cell growth. However, the assay was performed in serum 
obtained from peripheral blood, whereas cytokines are shown to be optimally 
active in the immediate environments of the tumor cells and are known to 
remain active for only a very short period of time. Kanayama et al have found 
that the serum from splenic venous blood of advanced gastric cancer patients 
possesses greater immuno-suppressive activity, compared to serum from peripheral 
blood[12]. This indicates a site dependent activity measurable in serum. It could 
be an important factor, contributing to our failure to detect any growth 
modifying capability of serum from transfused animals. Furthermore, the first 
serum sample was obtained one day after administration of blood transfusion, and 
it is possible that the changes in cytokines, sufficiently great to be detectable in 
serum, took place at an earlier stage. Recently, evidence has been 
presented[l3,14] indicating secretion of autocrine growth factor(s) by malignant 
cells. Blood transfusion may have stimulated the production of autocrine growth 
factor, with these factors being effective only in the direct vicinity of the cells. 
This could be yet another explanation for our failure to detect such factors in 
an in vitro assay. Although we were unable to observe effects to support our 
hypothesis regarding the induction of growth factor, other assays which take the 
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above mentioned importance of local environment into account may give a more 
meaningful answer regarding the validity of the hypothesis. 
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CHAPTER9 
CONSEQUENCES OF BLOOD LOSS ON GROWTH OF ARTIFICIAL METASTASES. 
This chapter will be published in The British J. of Surgery. 
Summary 
Previous studies have shown that the rate of growth of lung metastases from 
a non-immunogenic sarcoma (LS 175) in rats was greater in blood transfused 
rats. Enhanced growth was also observed after abdominal surgery combined with 
allogeneic blood transfusions. Syngeneic blood transfusions had no effect. These 
experimental findings have been confrrmed in retrospective clinical studies. The 
allogeneic blood tranfusion effect may be omitted in cancer patients by means 
of autologous blood transfusions. For such a transfusion policy, blood donation 
prior to surgery is needed. The aim of the present study was to investigate the 
effect of blood loss prior to surgery on formation ("Take") of lung colonies, and 
on the outgrowth of established metastases in the BN rat model. These aspects 
of tumor behaviour were also investigated in rats undergoing surgery and/or 
receiving blood transfusion after blood loss. The results indicate that blood loss 
has a profound stimulating effect on the growth of established metastases, but 
not on the "Take" of tumor cells. This stimulating effect was also found to be 
present when blood loss was combined with surgery, while previously, surgery 
alone was found to have no effect. Both allogeneic and syngeneic transfusions in 
combination with blood loss had a strong stimulating effect on growth of 
established lung metastases. The results indicate that blood loss may be an 
impmtant factor in determining the outcome of metastatic growth. 
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Introduction 
Blood transfusions appear to have numerous consequences which were never 
envisaged at the outset. In spite of careful blood donor screening, a substantial 
number of patients receiving transfusions experience some type of serious 
adverse effect, e.g. serum hepatitis, Acquired Immune Deficiency Syndrome, 
sensitization to foreign antigens. A well recognized beneficial effect is the 
longer survival of kidney grafts in recipients given blood transfusions prior to 
transplantation; this has also been confirmed in various animal models [1-3]. 
There is no agreement concerning the mechanism(s) responsible for this 
phenomenon, but the modulation of the host's immune response by blood 
transfusions has generally been implicated i.e. suppressor cell induction; anti-
idiotypic antibodies; non-specific immunosuppression [4-6]. Recent clinical 
retrospective studies have demonstrated an association between perioperative 
blood transfusions and tumor recurrence in surgically treated patients [7-10]. 
These fmdings are also supported by the results of experimental work in rats 
carried out by Francis et al[ll] and ours~lves. We have demonstrated a 
promoting effect of blood transfusion on growth of artificial metastases[12]. 
Several disorders in the immune system have been reported following surgical 
trauma. Riddle et al [13] have shown a decline in lymphocyte response to 
Phytohaemagglutinin in postoperative patients; Constantian et al[14] demonstrared 
the presence of an endogenous immunosuppressive polypeptide in serum of 
traumatized patients; Slade et al[15] have demonstrated a decrease in a multitude 
of immune parameters measured in vivo and in vitro in normal patients following 
nephrectomy. In cancer patients, it is often the case that the only curative 
treatment is surgical resection of the primary tumor. This is usually an extensive 
surgical procedure with profound blood loss, often involving subsequent blood 
transfusions. The results mentioned above on immunomodulation following blood 
transfusions and surgery, together with the retrospective data indicating a 
decreased survival rate in patients receiving blood transfusion and undergoing 
surgical procedures, indicate grave consequences for cancer patients. 
A possible solution might be to reduce the need for allogeneic blood 
transfusions, and thus avoid the subsequent effects on the patient's immune 
apparatus. The use of autologous blood transfusions would circumvent this 
hazard. This would involve collecting autologous blood from the patients prior to 
surgery. The technical feasibility of this procedure has already been demonstrated 
[16-17]. The consequences for the immune status of cancer patients of pre- and 
peroperative blood loss have, however, not yet been investigated. 
In the present communication we report on the effects of blood loss, surgery 
and subsequent blood transfusions on the growth of established tumor metastases, 
using a rat model. Furthermore, the effect of blood loss alone and in 
combination with blood transfusions on the "take" of tumor cells was studied, 
since this might be of consequence for the tumor cells released in patients due 
to manipulation of the tumor during surgery. 
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Material and methods 
Animals: Male rats of the inbred BN and WAG strains were used. The animals, 
aged 16-20 weeks, were bred under specific pathogen-free conditions. 
Tumor: Tumor LS 175 is a spontaneous, non-immunogenic sarcoma in BN rats. 
The tumor is maintained as a stationary culture in Dulbecco's minimum essential 
medium, supplemented with 10% fetal calf serum (FCS). To obtain cells for the in 
vivo experiments, free floating LS175 cell clumps were harvested from the tissue 
culture flasks and, after washing, were resuspended in Hank's balanced salt 
solution (HESS). Single cells were prepared by rinsing the suspension through a 
pipette. Viability was assessed by trypan blue exclusion and was between 90 and 
95%. 
Lung colonies assay: 2.5 x lOS tumor cells, suspended in a volume of 1 ml, were 
injected intravenously into experimental and control rats. The number of colonies 
developing in the lungs were counted after 27 days. The lungs were excised, 
rinsed in tap water and subsequently fixed in Bouin's solution. Tumor nodules on 
the lung surface, visible to the naked eye, were counted. 
Blood transfusions: BN rats received a single i.v. injection of 1 ml heparinized 
whole WAG blood or 1 ml of syngeneic blood. Control animals received no 
transfusions. 
Bood loss: A volume of 4 ml blood was bled from BN rats by means of a tail 
incision. This volume represents approximately 30% of the total blood volume of 
the rats used. 
Adamina! surgery: Under ether anesthesia, an ileum resection at a length of 5-
6 em was performed, followed by reanastomoses using continuous suturing with 
7.0 silk was performed. The procedure lasted 15-20 minutes, with an estimated 
blood loss of ± 2 mi. 
Satistical analysis: All data were analysed by two way testing according to 
"Mann-Whitney" test when comparing two groups; and employing "Kruskal-Wallis" 
test for simultaneous comparison of more then two groups. The experimental 
error rate was reduced by using the significance level of P < 0.01 [18]. 
Experimental design 
To investigate the effect on "Take" of tumor cells, animals were bled 7 days 
prior to tumor cell inoculation and subsequently given allogeneic or syngeneic 
blood transfusions on the day of tumor inoculation. To study the effect on 
"growth" of established lung metastases animals were bled 7 days after the tumor 
cell inoculation. On Day + 14, animals received syngeneic or allogeneic blood 
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large standard deviations, both were found to be significantly higher than the 
control group; P < 0.005 and P < 0.0001 respectively. There was no statistically 
significant difference between the 3 experimental groups. These results indicate a 
substantial stimulation of growth of established lung metastases following blood 
loss. 
Effects of bleeding, abdominal surgery and blood transfusions on growth of lung 
metastases. 
BN rats injected with tumor cells on Day 0 were bled on Day +7. On Day +14, 
groups underwent procedures as shown in Table 3; i.e. they received syngeneic or 
allogeneic blood transfusions; underwent abdominal surgery or additionally 
received blood transfusion. The control group was only maculated with tumor 
cells on Day 0. The results are presented in Table 3. The groups which were bled 
only, or additionally received syngeneic or allogeneic blood transfusions, showed 
a significantly higher number of lung colonies, as compared to the control group 
(P < 0.0002). This is in accordance with the results shown in Table 2. 
Furthermore, the number of colonies were significantly higher in the group 
receiving allogeneic transfusion in comparison to syngeneically transfused and the 
group of animals which were only bled. This illustrates the determental effect of 
blood transfusion superimposed on the effect of blood loss. The mean number of 
colonies of the group bled on Day + 7 and undergoing abdominal surgery on Day 
+ 14 was 76 ± 26, which is significantly higher than the mean of the groups 
bled, undergoing abdominal surgery and additionally receiving syngeneic or 
allogeneic blood transfusions had a mean number of colonies of 135 ± 53 and 179 
± 50 respectively, which is significantly higher than the control group. These 
results demonstrate stimulation of growth of lung metastases following blood loss 
alone, or in combination with blood transfusions and/ or abdominal surgery. 
Discussion 
Abraham et al [19, 20] reported a profound depression of inflammatory 
response and decreased mitogenic induced lymphocyte proliferation, following 
hemorrhage. Loegering et al[21] reported deficiency of circulating opsonic 
activity and reticulo-endothelial (RE) system depression during hemorrhagic 
shock. Also it is a well recognized fact in the clinic [22] that patients are 
susceptible to sepsis following trauma and hemorrhage. When entertaining the 
idea of autologous blood transfusion, bleeding the cancer patients prior to 
surgery would be a prerequisite. Considering the reports above, this prerequisite 
could have consequences for the "Take" of tumor cells released during 
manipulation of the primary tumor during surgery. The data in Table 1 show that 
blood loss on Day -7 did not have an effect on the "Take" of tumor cells on Day 
0. Subsequent syngeneic or allogeneic blood transfusions following blood loss also 
had no effect on "Take". In this tumor mode~ we have shown previously [12] 
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that blood transfusions on Day -7 had no effect on "Take" of tumor cells. A 
possible explanation could be that in the process of "Take" factors other than 
the immune status are of greater importance. These could be coagulation status 
at time of tumor inoculation; inter-tumor cell interaction; etc. The data 
presented in Table 2 demonstrate a stimulating effect of blood loss on the 
growth of established metastases. We have shown previously [12], that syngeneic 
blood transfusion does not affect the growth of established lung metastases in 
this tumor model. However, the present results show a stimulating effect in the 
group receiving syngeneic blood transfusion when combined with prior blood loss. 
A similar effect is also observed in the animals which were only bled. This 
indicates an overwhelming adverse effect of blood loss. The group which was 
given allogeneic blood also showed greatly enhanced growth of lung colonies, and 
these results are confirmed by the results in Table 3. To our knowledge the 
effect of blood loss, as stated above, has not previously been investigated. 
Hattari et al[23] have demonstrated enhancing effects on tumor growth and 
Jubert et al[24] have shown impairment of immunocompetence, following 
peroperative blood loss. Our results show a similar trend: an enhancing effect on 
tumor growth is observed in groups undergoing abdominal surgery and 
additionally receiving allogeneic or syngeneic blood transfusions, preceded by 
blood loss on Day + 7. An explanation for discrepancy between the effects of 
blood loss on "Take" and growth of established metastases could be the 
importance of different factors exhibiting a prominent role in the different 
phases of tumor kinetics. The assumed immunosuppresion produced by blood loss, 
blood transfusions and surgery might be responsible for the enhanced growth of 
metastases; while other factors, as stated above, play an eminent role in the 
outcome of "Take" of tumor cells. These results stress the need for further 
investigations of immunoparameters following a period of blood loss. 
Pre-operative blood donation for autologous blood transfusion is a very 
plausible solution for the reported detrimental effect of blood transfusion on 
survival rates of cancer patients undergoing surgery. Further investigations 
should certainly be carried out, but as shown in our tumor model the 
prerequisite for any autologous blood transfusion i.e. blood loss prior to surgery, 
may have serious consequences. 
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CHAPTER10 
ABROGATION OF THE TUMOR PROMOTING EFFECT OF ALLOGENEIC BLOOD 
TRANSFUSION BY POLYADENYLIC-POLYURIDYLIC ACID(POLY A-POLY U) 
This chapter was published in Cancer Immunology and immunotherapy 1987; 
25:242-244. 
Summary 
Surgical procedures have been shown to have an immunosuppressive effect. 
Retrospective studies have shown blood transfusions to be associated with an 
adverse prognosis of surgically treated cancer patients. We have previously 
demonstrated an enhanced growth of tumor metastases,in rats, following 
allogeneic blood transfusion and surgery. Poly A-poly U has been reported to 
stimulate immune responses. In this report, we have investigated the 
effectiveness of poly A-poly U as an adjuvant to blood transfusion and surgical 
procedures in BN rats bearing artificial lung metastases. Significantly reduced 
tumor growth was observed following poly A-poly U adjuvant treatment. 
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Introduction 
The current therapeutic approach to treatment of cancer patients is 
multi-disciplinary. Surgical, hormonal, immune and radio-chemo-therapy play the 
major role. Many studies have indicated an immuno-suppressive effect of several 
treatment modalities. Stratton et al [1] have shown a profound effect of 
irradiation on lymphocyte subpopulations in cancer patients. Various 
chemotherapeutic regimes are known to produce an immunosuppressive effect[2]. 
Numerous reports have indicated the most commonly employed therapy for cancer 
patients, i.e.: surgical resection, to have an immunosuppressive effect[3,4]. 
Anesthesia, the inevitable accompaniment of a surgical procedure, is also shown 
to have similar effects on the immune apparatus[5]. Furthermore, surgery in 
cancer patients is often accompanied by substantial blood loss, necessitating 
administration of a blood transfusion. Blood loss on its own has been shown to 
produce decreased immuno-competence [6,7]. Several recent retrospective studies 
have indicated a relationship between blood transfusions and adverse prognosis of 
disease-free survival of surgically-treated cancer patients [8,9] and has been 
subsequently been confirmed in animal studies[lO,ll]. In a rat mode~ we 
previously demonstrated a detrimental effect of surgery in combination with 
allogeneic blood transfusion on the growth of established artifical tumor 
metastases[12,13]. Surgical treatment of cancer patients may result in marked 
immunosuppression and eventual enhancement of tumor metastatic growth. 
A double-stranded synthetic polynucleotide, polyadenylic-polyuridylic acid (poly 
A - poly U), has been reported to stimulate immune responses. It has been 
shown to possess an anti-tumor effect, and to be a potent immune modulator of 
both the humoral and cellular immune response and to result in enhancement of 
natural killer cell activity (NK cell)[14-18]. Furthermore, no toxic or pyrogenic 
effects of poly A - poly U have been reported even when used at high dosage, 
as adjunct in cancer therapy[19,20]. 
Previously, we have shown an enhanced growth of LS 175 tumor metastases in 
BN rats undergoing abdominal surgery in combination with allogeneic blood 
transfusion. Enhanced metastases growth is also observed following allogeneic 
blood transfusion alone[ll-13]. This enhanced growth is found to be correlated 
with decreased T -cell activity (chapter 7). In the present manuscript we report 
on the effect of adjuvant treatment with poly A-poly U in tumor-bearing rats 
undergoing abdominal surgery and treated with blood transfusions. 
Material and methods 
Animals: Male rats of the inbred BN and WAG strains were used. The animals, 
aged 16-20 weeks, were bred under specific pathogen free conditions. 
Tumor: Tumor LS 175 is a spontaneous, non-immunogenic sarcoma in BN rats. 
The tumor is maintained as a stationary culture in Dulbecca's minimum essential 
medium, supplemented with 10% fetal calf serum (FCS). To obtain cells for the 
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vivo experiments, free-floating LS 175 cell clumps were harvested from the tissue 
culture flasks and, after washing, were resuspended in Hank's balanced salt 
solution (HESS). Single cells were prepared by rinsing the suspension through a 
pipette. Viability was assessed by trypan blue exclusion and was between 90 and 
95%. 
Lung colonies assay: 2.5 X loS tumor cells, suspended in a volume of 1 ml, 
were injected intravenously into experimental and control rats. The number of 
colonies developing on the lungs were counted after 24 days. The lungs were 
excised, rinsed in tap water and subsequently fixed in Bouin's solution. Tumor 
nodules on the lung surface, visible to the naked eye, were counted. 
Blood transfusions: BN rats received a single i.v. injection of 1 ml heparinized 
whole allogeneic blood or 1 ml of syngeneic blood. Control animals received no 
transfusions. 
Abdominal surgery: Under ether anesthesia a resection of a 5-6 em segment of 
ileum was performed followed by end-to-end anastomoses using continous suturing 
with 7.0 silk. The procedure lasted 15-20 minutes, with an estimated blood loss 
of ±2ml. 
Poly A -poly U: Poly A-poly U (Sigma P3259) powder was dissolved in 
phosphate buffered saline (PBS) and adjusted to a concentration of 3000J.Lg/ml. 
0.5 ml i.e.: 1500 J.L g, of this solution was administered intravenously (i.v.) to 
experimental animals on days + 7, + 14 and + 21. 
Experimental design 
The effectiveness of poly A-poly U in abrogating the adverse effect of 
allogeneic blood transfusion alone or in combination with surgery, on the growth 
of established lung metastases was investigated. BN rats were inoculated with 
2.5 X loS LS 175 tumor cells on day 0. The control animals did not receive any 
blood transfusion or poly A-poly U and did not undergo abdominal surgery. On 
day +7, experimental groups of animals received syngeneic or allogeneic blood 
transfusion alone or in combination with abdominal surgery. A group of rats 
underwent abdominal surgery but received no blood transfusion and another 
group was administered poly A-poly U alone without undergoing surgery or blood 
transfusion. All experimental groups were administered poly A-poly U in a dosage 
of 1500J,Lgjweek, on days +7, +14 and +21. Animals were sacrificed on day +24 
and lung colonies were counted. Each group comprised 9-15 animals. The results 
were statistically analysed by means of the Student "t" test. 
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Table 1: Effect of poly A - poly U as adjuvant therapy on tumor growth. 
Treatment on day + 7 
No treatment 
Poly A-Poly U only 
Syngeneic transfusion+ 
Poly A-Poly U 
Allogeneic transfusion + 
Poly A-Poly U 
Surgery+ 
Poly A-Poly U 
Surgery+ Syngeneic 
transfusion+ Poly A-Poly U 
Surgery + Allogeneic 
transfusion + Poly A-Poly U 
No. of 
animals 
15 
10 
10 
10 
9 
9 
9 
Mean no. of lung 
colonies (± S.D.) 
60± 14 
39± 7 
20± 4 
33 ± 10 
26± 6 
40± 9 
28± 4 
* 
s 
s 
s 
s 
s 
s 
poly A- poly U administered in a doses of 1500,ug/wk on days +7; +14; and +21 
after tumor inoculation. 
* : Significantly different as compared to the control group. 
Results 
On day + 24 the mean number of colonies of the control group, i.e.: animals 
inoculated with tumor cells on day 0 not undergoing any further experimental 
procedure, was 60 ± 14 (Table 1). All other experimental groups were treated 
with poly A-poly U on days +7, +14 and +21. Treatment with poly A- poly U 
alone resulted in 39 ± 7 lung colonies, which is significantly less than the 
control group. Syngeneic and allogeneic blood transfusion combined with poly 
A-poly U resulted in 20 ± 4 and 33 ± 10 lung colonies, respectively. These 
numbers were significantlylower than the control group. Surgery alone or in 
combination with blood transfusion and adjuvant poly A-poly U treatment also 
resulted in a significantly lower mean number of lung colonies. Surgery alone 
resulted in a mean number of lung colonies of 26 + 6, while in combination with 
syngeneic and allogeneic transfusion 40 ± 9 and 28 ± 4 lung colonies were found, 
respectively. These results indicate a profound suppressive effect on the growth 
of established lung tumor metastases following adjuvant treatment with poly 
A-poly U, even when the animals underwent surgery and received allogeneic 
blood transfusion. 
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Discussion 
Lundy et al[21] have shown that the use of Thiobendazole, an 
immuno-restorative drug, as immunotherapy can be an effective adjuvant 
treatment to surgery in preventing the growth of micro-metastic foci. Lacour et 
al[22] have demonstrated a significant benefit of adjuvant treatment with poly 
A-poly U in operable breast cancer patients, demonstrating an increase in both 
overall and relapse free survival, particularly in the group with positive axillary 
nodes. Bonadonna et al[23] have reported similar success in treating breast 
cancer patients with CMF ( cyclophasphamide, methotrexate and flourouracil) as 
adjuvant therapy. However, in contrast to poly A-poly U, several side-effects 
following CMF use were reported. The results of this study confirm the 
beneficial use of poly A-poly U, a immuno-stimulatory drug, as adjuvant in 
cancer therapy. Previously, in the same tumor-host model employed in this study, 
we have demonstrated a significant enhancement of tumor growth following 
allogeneic blood transfusion alone or in combination with abdominal surgery 
[11-13]. These animals also showed a significantly diminished mitogen blastogenic 
response to Con A and PHA stimulation. In the present study, poly A-poly U is 
shown to be effective in abrogating the adverse effect of blood transfusion and 
surgery on tumor growth. In the same tumor-host model, poly A-poly U 
treatment was found to result in a significant stimulation of mitogen blastogenic 
response and gamma-interferon production capacity[18]. Youn et al[24] have 
shown a significant enhancement of NK cell activity following poly A-poly U 
treatment of operable stomach cancer patients. The anti-tumor and the 
stimulating effect on cellular immune response, NK cell activity and interferon 
production capacity of poly A-poly U treatment could be the mechanisms 
responsible for offsetting the detrimental effects of surgery and blood 
transfusions, and resulting in a significantly diminished growth of tumor 
metastases [14-16,25]. 
Surgical resection is still the most frequent therapy employed in treatment of 
cancer patient. In spite of improved surgical techniques, perioperative blood loss 
often necessitates the administration of a blood transfusion. Recent retrospective 
studies indicate an adverse effect of blood transfusion on disease-free survival[8, 
9]. This blood transfusion effect could lead to restrictions in the surgical 
procedures employed in treating cancer patients. Thus, one should consider the 
use of immuno-restorative adjuvant therapy in surgical treatment, especially when 
blood transfusions are also administered. The absence of any reported toxic, 
pyrogenic or other secondary effect of poly A-poly U and its demonstrated 
effective employment as adjuvant chemotherapy agent in clinical studies, makes 
poly A-poly U a strong candidate for use as described[19]. The results of the 
present study and other experimental studies further substantiate the 
effectiveness of its use. 
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CHAPTERll 
GENERAL DISCUSSION 
The present study demonstrates that allogeneic blood transfusions are capable 
of modulating different processes of tumor progression. In two different tumor-
rat models varied effects were observed: blood transfusion in one model was 
found to inhibit the take but have no effect on growth of established artificial 
tumor metastases; whereas in the other, transfusion had no effect on take but 
strongly stimulated the growth of the metastases(Table 1). Erythrocyte and 
leukocyte transfusates were as effective as whole blood in stimulating growth, 
whereas plasma transfusion failed to have an effect[ chapter 4,6]. 
Table 1: Summary. 
Experimental procedure 
Allogeneic blood transfusion 
Allogeneic blood transfusion 
Surgery 
Allogeneic blood transfusion + Surgery 
Allogeneic erythrocytes transfusion 
Allogeneic leukocytes transfusion 
Allogeneic plasma transfusion 
Tumor 
Tumor LS 175 
Tumor BC 1618 
Tumor LS 175 
Tumor LS 175 
Tumor LS 175 
Tumor LS 175 
Tumor LS 175 
Tumor· take Tumor·growth 
No effect Stimulation 
Inhibition No effect 
Stimulation No effect 
Stimulation 
Stimulation 
Stimulation 
No effect 
These diverse effects of blood transfusion are similar to the results found in 
clinical retrospective studies ie: some studies find a correlation between poor 
prognosis of surgically treated cancer patients and blood transfusions, while 
other studies fail to confirm such a relationship [chapter 2]. A comparative array 
of effects is found in studies on the effect of blood transfusions on prognosis of 
an organ transplant, in clinical and experimental animal studies. A prolonged 
graft survival is reported in patients, and in animal models, transfused prior to 
transplantation[1,2], whereas various studies have reported no beneficial effect 
using donor-specific or third party blood transfusions[3,4]. In the WAG to BN 
heart transplantation model, a donor specific transfusion results in sensitization, 
reflected in accelerated graft rejection. In our studies, however, a WAG 
allogeneic blood transfusion to BN rats was found to stimulate syngeneic tumor 
growth, which would seem to contradict the immunostimulatory effect observed in 
the organ graft model. However, recent preliminary results indicate that a blood 
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transfusion, parallel to donor specific sensitization can induce a degree of 
aspecific immunosuppression, as reflected in prolonged survival of a third party 
organ graft (Singh, unpublished data). This indicates the existence of paradoxical 
specific and non-specific immunological effects of blood transfusion in the same 
blood recipient at the same time. Furthermore, as opposed to the situation in the 
transplantation model, it is the effect of a third party blood transfusion which is 
observed in the tumor growth model. Some authors have put forward that 
immunosuppression in a transplantation model following blood transfusion is the 
result of leukocytes in the transfusate. However, the merits if this argument 
cannot be investigated, since there is always a degree of leukocyte 
contamination, irrespective of the method used for purification. Furthermore, we 
[chapter 6] and Oikawa et al[S] have demonstrated that the effect of blood 
transfusion as observed on tumor growth can be elicitated by administration of 
erythrocytes and leukocytes alone. Thus, the detrimental effect of transfusion on 
tumor growth could not be avoided by employing a leukocyte-free erythrocyte 
transfusion. 
In accordance with the results of organ transplantation models, the blood 
transfusion effect on tumor growth is found to be dependent on several factors 
i.e.: the tumor employed, and the blood donor-recipient combination. Jeekel et 
al., employing WAG rats bearing a transplantable adeno-carcinoma, reported 
inhibition of tumor growth after a BN rat whole blood transfusion, as opposed to 
no effect in WAG rats on tumor BC 1618 observed in our studies[S]. Other 
experimental studies, investigating this blood transfusion phenomenon, also 
demonstrate a similar variety of effects on tumor growth. Francis et al., in a rat 
tumor model, have reported an enhanced tumor growth following an allogeneic 
transfusion[6]. In other tumor models Oikawa et al., Zeller et al. and Nathanson 
et al. have shown effects ranging from inhibitory to no effect on tumor 
growth[7-9]. 
Factors other than blood transfusion could be the culprits responsible for the 
poor prognosis of surgically-treated patients found in the retrospective studies. 
In our study, we found no effect of anesthesia on tumor growth. However, a 
profound enhancing effect of abdominal surgery on the take of tumor cells was 
demonstrated [chapter 5]. This could be of great consequence for the take of 
tumor cells released by tumor manipulation during surgical tumor resection. To 
avoid such an effect, the no-touch technique, though not proven to lead to a 
decreased number of metastases, might be recommended as the surgical procedure 
of choice. 
Eggermont et al., in a mice-tumor model, have shown an augmentation of 
tumor growth following a surgical procedure[10]. In the BN-LS 175 tumor model, 
abdominal surgery was found to have no effect on the growth of established 
metastases. However, strong stimulation of metastatic growth was observed after 
abdominal surgery in combination with allogeneic blood transfusion. Whether this 
effect is evoked by allogeneic blood transfusion alone or amplified by the 
surgical stress, is open to speculation. 
The difference in effects of blood transfusion, surgery alone or surgery 
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combined with transfusion, on different stages of tumor progression may be 
explained by the relative importance of different host and tumor factors during 
various stages. NK cell activity is believed to be of consequence for the take of 
tumor cells, while being less effective on the growth of established 
metastases[ll]. However, a significant increase in NK cell activity was observed 
after abdominal surgery, which was found to enhance, rather than inhibit, the 
take of tumor cells [chapter 5,7]. This indicates that factors other than NK 
cells may be of crucial importance. In the results reported in chapter 7, a 
correlation was found between enhanced tumor growth and a decrease in T -cell 
mitogen stimulation response, following allogeneic blood transfusion alone or in 
combination with surgery. Francis et al. and Nathanson et al. have also shown a 
similar depression of T-cell activity after allogeneic blood transfusion[5,7]. 
Acceleration of tumor growth was also observed following cyclosporin treatment 
(chapter 7), a drug believed to specifically inhibit T -cell function, providing 
indirect evidence of susceptibility of the tumor to T -cells. Furthermore, poly 
A-poly U, an immunomodulator capable of enhancing the cellular immune 
response, was found to be effective in eliminating the detrimental effect of 
allogeneic blood transfusion [chapter 10]. These results indicate a certain role of 
T-cells in the blood transfusion phenomenon. However, the tumor used in our 
studies, LS 175, is known to be non-immunogenic and thus would not be expected 
to be affected by changes in the host's T-cell dependent immune status. In spite 
of enormous growth in the number of publications each year, our knowledge of 
non-immunogenic tumors, a category to which most human cancers belong, is 
extremely rudimentary. Most of the reports in the literature use a chemically or 
virally-induced immunogenic tumor. In a random selection of papers published in 
one year, Hewitt et al.[12] found that in less than 7% of the cases a spontaneous 
tumor, which is mostly non-immunogenic, was used. Because of this lack of 
knowledge about the manner of interaction between an non-immunogenic tumor 
and the immune apparatus of the host, no classical explanation for the possible 
correlation between T -cell function and growth of LS 175 can be presented. It is 
generally assumed that so called non-immunogenic tumors are not capable of 
inducing specific immunity which influences the growth of the tumor after 
immunization. However, a degree of specific control may be exercised by the 
immune apparatus, in spite of the measure of tumor growth observed. Disturbance 
of this equilibrium between immunological control and tumor growth, may lead to 
modulation of tumor growth. Although the above hypothesis is speculative, a 
similar equilibrium is believed to be functional for the dormant cancer cell, a 
phenomenon in which recurrence of cancer may occur after a latent period of up 
to 30 years[12,13]. Furthermore, the classification immunogenic versus non-
immunogenic is dependent on the tools employed during this procedure. The use 
of other or more sensitive assays could lead to a different classification of the 
same tumor. 
Factors not related to T -cells may be of importance in precipitation of the 
blood transfusion phenomenon. Rather than immunological factors, polypeptide 
hormones and hormone like growth factors may be the prominent agents in the 
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tumor growth modulation observed. Malignant cells have been shown to be 
capable of producing growth factors which stimulate their own growth, thus 
rendering them independent of serum factors[14]. This property of cancer cells 
may be of crucial importance in the growth of established tumor metastases. 
These mediators are often only produced locally and in extremely small amounts, 
and vanish rapidly. We were unable to detect tumor growth factors after blood 
transfusion and surgery. However, our assay is a reflection of the factors present 
in peripheral blood, whereas factors obtained from the local enviroment of 
metastases could be more representive for the status assay. Similarly, the immune 
parameters were determined in peripheral blood and spleen cells; these may not 
correlate intimately with the immune status in and around the tumor metastases. 
The evolution of techniques of immunohistochemistry and monoclonal antibodies 
at present allow the identification of various immunological cells and their 
functional subsets. Employment of such methods in evaluating populations of cells 
and vatious growth mediators in and around the immediate vicinity of tumor cells 
could provide a better understanding of the role of different factors in tumor 
biology. 
In recent years, much attention has been focused on prostaglandins(PGs). 
T -lymphocytes, macrophages and tumor cell are all capable of PG production, 
especially prostaglandins E (PGE). A marked increase of PG production is 
reported in malignant tumors[15,16]. Kort et al., using the BN-LS 175 model, the 
same combination as employed in our studies, have demonstrated high plasma 
tromboxane B2 and PG~ levels with growth of the tumor, and decrease of 
metastatic growth with aspirine therapy[17,18]. Recently, a significant increase in 
prostaglandin E production after blood transfusion has been reported [19-21]. 
Furthermore, Shelby et al. have shown that the blood transfusion induced 
suppression of a graft-vs-host response in rats was abrogated by concomitant 
treatment with indomethacin[22]. If these observations are taken together they 
indicate a possible role for the PGs in the mechanism of the blood transfusion 
phenomenon in relation to cancer growth. Investigations to elucidate this 
speculation may provide clues as to the enigma of the blood transfusion 
phenomenon. 
Investigations reported in this thesis demonstrate that allogeneic blood 
transfusion can result in enhanced tumor growth. However, the results of an 
ongoing prospective clinical trial on the effect of blood transfusions on the 
outcome of colon cancer patients, in Rotterdam, should provide the ultimate 
answer to the question whether the transfusion phenomenon demonstrated in our 
study is an artefact or reality in the clinical setting. 
Finally, while the blood transfusion may be inevitable, the subsequent 
administration of immune-modulators e.g.: poly A-poly U may help to counteract 
its detrimental effect. This approach requires further investigation. 
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CHAPTER12 
SUMMARY 
In the course of their treatment, cancer patients frequently require blood 
tran~fusions. In the field of transplantation, blood transfusions have been 
demonstrated to result in prolonged organ graft survival. The proposed existence 
of an analogy between the antigenicity of an organ graft and a tumor raises the 
question of a possible relationship between tumor growth and blood transfusion. 
The experiments described in this thesis investigated various aspects of surgical 
treatment of a cancer patient, including blood transfusions, on tumor behaviour 
in an experimental model. A short review of the relevant aspects of immunology 
with respect to tumors, as they may relate to blood transfusions, is presented in 
chapter 1. Chapter 2 furnishes the detailed arguments which form the basis of 
the experiments in this thesis. Results of clinical and experimental investigations 
demonstrate an array of effects ranging from inhibition to no effect to 
stimulation of tumor growth following blood transfusion. Clarifying remarks, 
thought to be helpful in the interpretation of the results reported in the thesis, 
are made in chapter 3. 
Allogeneic blood transfusion was found to be capable of modulating tumor 
growth in two different tumor models in rats( chapter 4). A single blood 
transfusion was found to stimulate the growth of tumor LS 175, a non-
immunogenic sarcoma transplantable in BN rats, but had no effect on the take of 
the tumor. However, in the BC 1618 tumor model, a highly immunogenic basal 
cell carcinoma, transplantable in WAG rats, no effect on growth and inhibition of 
the take of the tumor was observed. This demonstrates that the mode of tumor 
growth modulation following transfusion is dependent on the tumor and host 
employed and the aspect of tumor kinetics investigated. An effect on tumor 
growth was assumed to have been observed if blood transfusion was administered 
after tumor inoculation, the take of the tumor was assumed to be modified if 
transfusion was given before tumor injection. 
Investigations into other aspects of surgical treatment were carried out by 
employing a tumor-host model in which transfusion resulted in enhanced tumor 
growth, i.e.: the LS 175 model in BN rats. In this model BN rats recieved 2.5 x 
loS tumor cells i.v. leading to the development of artificial lung metastases, and 
then underwent the experimental procedure under study. The number of lung 
metastases counted four weeks after tumor inoculation was the fmal assay of the 
experiments. Neither an ether anesthesia nor surgery alone was found to have an 
effect on the growth of tumor LS 175. However, abdominal surgery in 
conjunction with allogeneic blood transfusion significantly increased tumor 
growth (chapter 5). Furthermore, surgery itself was found to increase greatly the 
take of the tumor cells. 
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Some authors claim that the blood transfusion effect in organ transplantation 
is the result of the presence of leukocytes in the transfusate. Results in support 
as well as against this school of thought can be found in the literature. This led 
us to investigate the role of different blood constituents on tumor growth. 
Erythrocytes and leukocytes were found to be capable of stimulating tumor 
growth, similar to the effect of whole allogeneic blood. However, a plasma 
transfusion was found to have no effect (chapter 6). 
One of the reasons for the administration of blood transfusions to a cancer 
patient undergoing surgery is pre-, per- or post-operative blood loss. The effect 
of blood loss on tumor growth has not been appropriately investigated and so we 
looked at its consequences in the LS 175 tumor model. We found that a blood 
loss of approximately 30% of the total blood volume, alone or in combination 
with surgery and blood transfusion, strongly stimulated the growth of artificial 
lung metastases (chapter 9). Thus, in the clinical retrospective studies, reporting 
on the effect of transfusion on tumor growth, blood loss may have been an 
important factor which was not taken into consideration. 
The positive effect of transfusion on organ graft survival is thought to be 
due to an immunosuppressive effect of transfusions. However, the mechanism 
underlying this is not yet known. We have investigated the possible role of the 
immune system in the blood transfusion effect in relation to cancer (chapter 7,8). 
An allogeneic blood transfusion was found to result in a decreased T -cell 
activity, which may reflect a mechanism precipitating the blood transfusion 
phenomenon. However, following surgery and transfusion the natural killer cell 
and the leukocyte phagocytic activity significantly increased. This increase did 
not correlate with the observed tumor growth and did not appear to have a role 
in modulation of tumor behavior (chapter 7). Furthermore, an immune modulator, 
Poly A- Poly U, was found to be successful in abrogating the detrimental effect 
of blood transfusion on tumor growth. This provides further credence for the 
blood transfusion phenomenon, as observed here, to be an immunological 
phenomenon. 
Factors not related to immunology may also be of importance. We attempted 
to fmd a possible role of growth factors in the transfusion phenomenon, but 
were unsuccessful. Finally, other possible mechanisms and future consequences of 
the blood transfusion phenomenon reported here are discussed in chapter 11. 
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CHAPTER13 
SAMENVATIING 
Kankerpatienten die voor hun tumor worden geopereerd krijgen vaak 
bloedtransfusies. Uit de transplantatiebiologie is bekend dat bloedtransfusies 
immunosuppressie veroorzaken en de acceptatie van orgaantransplantaten 
verbeteren. Indien men de hypothese aanhangt dat een tumor, net zoals een 
transplantliat, immunogeen is voor zijn gastheer, dringt zich de vraag op of bij 
kankerpatienten bloedtransfusies de groei van tumoren zouden kunnen 
beinvloeden. 
Behalve bloedtransfusies zijn er ook andere aspecten rond een operatie die 
mogelijk van invloed zijn op het gedrag van een tumor; anesthesie, de 
chirurgische ingreep zelf en bloedverlies. De e:xperimenten die in dit proefschrift 
beschreven staan hadden tot doel inzicht te verschaffen in de afzonderlijke 
betekenis van deze aspecten voor de groei van tumoren. Voor het onderzoek 
werd gebruik gemaakt van twee tumormodellen bij de rat. 
In hoofdstuk 1 wordt een overzicht gegeven van de recente inzichten in de 
tumorimmunologie. In hoofdstuk 2 staan de e:xperimentele en klinische resultaten 
vermeld die de hypothese dat er een verband zou zijn tussen bloedtransfusies en 
tumorgroei steunen dan wei omver werpen. Hoofdstuk 3 geeft een nadere 
toelichting op de in dit proefschrift gebruikte tumormodellen, waardoor de 
interpretatie van de behaalde resultaten meer inzichtelijk wordt. 
In hoofdstuk 4 staan e:xperimenten beschreven waarin het effect van 
bloedtransfusies in twee tumormodellen werd bestudeerd. In het eerste model 
werd gebruik gemaakt van een niet-immunogeen sarcoom bij ingeteelde BN ratten. 
Allogene transfusies gaven aanleiding tot een versnelde groei van deze tumor, 
maar hadden geen invloed op het aanslaan van ( artificiele) metastases. Het 
tweede model bestond uit een sterk immunogene huidtumor bij ingeteelde WAG 
ratten. De groei van deze tumor werd niet door allogene transfusies beinvloed, 
echter het aanslaan van longmetastasen werd door transfusies aanzienlijk geremd. 
Deze sterk wisselende resultaten lijken aan te geven dat het transfusie-effect 
wordt bepaald door zowel factoren in de tumor als in de gastheer. Het eerste 
tumor model werd verder aangewend om de rol van chirurgie en ether anesthesie, 
al of niet in combinatie met bloedtransfusies te bestuderen (hoofdstuk 5). De 
procedure was als volgt: BN ratten kregen 2.5xloS sarcoomcellen intraveneus 
toegediend wat leidt tot de ontwikkeling van longmetastasen die na 4 weken goed 
te tellen zijn. De te onderzoeken variabelen (transfusie, chirurgie, anesthesie) 
werden voor of na de inoculatie van tumorcellen toegediend, zodat de invloed op 
respectievelijk het aanslaan dan wei de uitgroei van de tumor kon worden 
bestudeerd. Ether anesthesie en chirurgie, welke bestond uit het verwijderen van 
een stukje dunne darm, hadden geen invloed op de groei van gevestigde 
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longmetastases. Echter, chirurgie gecombineerd met een allogene bloed transfusie 
had weer een sterk stimulerend effect. Het aanslaan van de tumor werd 
aanzienlijk bevorderd door chirurgie. 
In hoofdstuk 6 worden experimenten beschreven die tot doel hadden de 
invloed van verschillende bloedcomponenten op tumorgroei te bestuderen. 
Gezuiverde leukocyten en erythrocyten suspensies waren beide in staat het 
bloedtransfusie fenomeen te induceren terwijl plasma geen effect had. 
Een belangrijke reden om peroperatief bloed aan kankerpatienten 
toe te dienen is bloedverlies. Over het effect van bloedverlies op tumorgedrag is 
weinig bekend, reden om dit te bestuderen in ons tumormodel. Er werd gevonden 
dat verlies van ongeveer 30% van het totale bloedvolume de groei van 
longmetastases sterk stimuleerde, ook indien dit werd gecombineerd met chirurgie 
of bloedtransfusies (hoofdstuk 9 ). Deze bevinding geeft aan dat bij de 
interpretatie van de retrospectieve klinische gegevens over de relatie 
bloedtransfusies- tumorgroei, ernstig rekening gehouden moet worden met de 
additionele rol van bloedverlies. 
Het positieve effect dat bloedtransfusies hebben op de acceptatie van 
orgaan transplantaten wordt toegeschreven aan de inductie van 
immunosuppressie. Ook in ons tumormodel hebben we onderzocht of er een 
relatie bestond tussen het immuunsysteem en het groeigedrag van de tumor na 
bloedtransfusies en chirurgie (hoofdstukken 7 en 8). De belangrijkste bevinding 
was dat allogene transfusies resulteerden in een verminderde T -eel respons. De 
activiteit van NK-cellen en de fagocytose capaciteit van leukocyten daarentegen 
bleken verhoogd na bloedtransfusies en chirurgie. In aanmerking genomen dat het 
sarcoom dat werd gebruikt tijdens deze studie niet-immunogeen is en 
dientengevolge ongevoelig zou moeten zijn voor een klassieke T -eel depressie 
maar gevoelig voor modificaties in natuurlijke immuniteit, zijn de door ons 
gevonden immunologische bevindingen moeilijk in een begrijpelijk kader te 
vatten. De resultaten die staan vermeld in hoofdstuklO, en handelen over het 
vermogen van de immunomodulator poly A-poly U om het transfusie effect teniet 
te doen, doen eveneens vermoeden dat het immuunsysteem op onbegrepen wijze 
betrokken is bij de beschreven fenomenen. 
In hoofstuk 11 wordt nader ingegaan op het mogelijke mechanisme van het 
transfusie-effect en wordt aangegeven dat prostaglandines en groeifactoren mede 
van belang zouden kunnen zijn. 
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